Extensive	O
evidence	O
gathered	O
from	O
structure	O
-	O
activity	O
relationship	O
analysis	O
has	O
identified	O
and	O
confirmed	O
specific	O
positions	O
in	O
the	O
glucagon	O
sequence	O
that	O
are	O
important	O
either	O
for	O
binding	O
to	O
its	O
receptor	O
or	O
for	O
signal	O
transduction	O
.	O
These	O
diastereoisomers	O
were	O
formed	O
in	O
unequal	O
amounts	O
when	O
1	O
,	O
its	O
hexadeuterated	O
analogue	O
8	O
or	O
heptadeuterated	O
analogue	O
9	O
,	O
were	O
incubated	O
in	O
the	O
presence	O
of	O
the	O
rat	O
liver	O
microsomal	O
fraction	O
.	O
The	O
in	O
vitro	O
screening	O
for	O
trypanocidal	O
activity	O
against	O
Trypanosoma	O
brucei	O
rhodesiense	O
of	O
an	O
in	O
-	O
house	O
library	O
of	O
62	O
compounds	O
[	O
i.e.	O
alkane	O
,	O
diphenyl	O
,	O
and	O
azaalkane	O
bisguanidines	O
and	O
bis	B-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminoimidazolines	I-IUPAC
)	I-IUPAC
]	O
,	O
which	O
were	O
chosen	O
for	O
their	O
structural	O
similarity	O
to	O
the	O
trypanocidal	O
agents	O
synthalin	O
(	O
1,10	B-IUPAC
-	I-IUPAC
decanediguanidine	I-IUPAC
)	O
and	O
4,4	B-IUPAC
'	I-IUPAC
-	I-IUPAC
diguanidinodiphenylmethane	I-IUPAC
and	O
the	O
polyamine	B-IUPAC
N	I-IUPAC
(	I-IUPAC
1	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
)	I-IUPAC
propane	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
diamine	I-IUPAC
,	O
respectively	O
,	O
is	O
reported	O
.	O
The	O
metabolites	O
were	O
isolated	O
in	O
crystalline	O
form	O
from	O
urine	O
for	O
structure	O
determination	O
.	O
A	O
series	O
of	O
2	B-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	O
and	O
2	B-IUPAC
-	I-IUPAC
aryl	I-IUPAC
-	O
substituted	B-MODIFIER
8	B-PARTIUPAC
-	I-PARTIUPAC
hydroxy	I-PARTIUPAC
-	I-PARTIUPAC
,	O
8	B-PARTIUPAC
-	I-PARTIUPAC
methoxy	I-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
8	B-IUPAC
-	I-IUPAC
methylquinazolin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
has	O
been	O
synthesized	O
and	O
evaluated	O
for	O
PARP	O
inhibitory	O
activity	O
in	O
permeabilized	O
L1210	O
murine	O
leukemia	O
cells	O
.	O
On	O
the	O
basis	O
of	O
our	O
previous	O
observation	O
that	O
N1	B-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
substituted	B-MODIFIER
chlorpropamide	B-IUPAC
derivatives	B-MODIFIER
when	O
administered	O
to	O
rats	O
nonenzymatically	O
eliminated	O
n	B-IUPAC
-	I-IUPAC
propyl	I-IUPAC
isocyanate	I-IUPAC
,	O
a	O
known	O
inhibitor	O
of	O
aldehyde	O
dehydrogenase	O
(	O
AlDH	O
)	O
,	O
we	O
have	O
synthesized	O
other	O
latentiated	O
n	B-IUPAC
-	I-IUPAC
propyl	I-IUPAC
isocyanates	I-IUPAC
as	O
in	O
vivo	O
inhibitors	O
of	O
AlDH	O
.	O
Several	O
subsequent	O
analogues	O
,	O
including	O
the	O
2	B-IUPAC
-	I-IUPAC
chlorobenzoyl	I-IUPAC
(	O
18	O
)	O
,	O
(	B-IUPAC
3	I-IUPAC
-	I-IUPAC
chlorothiophene	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
carbonyl	I-IUPAC
(	O
51	O
)	O
,	O
(	B-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,2	I-IUPAC
-	I-IUPAC
dimethylcyclopropyl	I-IUPAC
)	I-IUPAC
carbonyl	I-IUPAC
(	O
80	O
)	O
,	O
and	O
tert	B-IUPAC
-	I-IUPAC
butoxycarbonyl	I-IUPAC
(	O
92	O
)	O
derivatives	B-MODIFIER
,	O
were	O
highly	O
effective	O
in	O
rats	O
,	O
surpassing	O
9	O
and	O
losartan	O
in	O
duration	O
of	O
action	O
and	O
/	O
or	O
potency	O
.	O
Pyrrole	B-IUPAC
bis	I-IUPAC
(	I-IUPAC
carbamates	I-IUPAC
)	I-IUPAC
20	O
and	O
21	O
,	O
which	O
exhibited	O
antileukemic	O
activity	O
,	O
also	O
showed	O
reactivity	O
toward	O
4	B-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
nitrobenzyl	I-IUPAC
)	I-IUPAC
pyridine	I-IUPAC
while	O
the	O
inactive	O
bis	B-IUPAC
(	I-IUPAC
carbamates	I-IUPAC
)	I-IUPAC
were	O
unreactive	O
in	O
the	O
4	B-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
nitrobenzyl	I-IUPAC
)	I-IUPAC
pyridine	I-IUPAC
assay	O
.	O
The	O
affinity	O
of	O
6beta	B-IUPAC
-	I-IUPAC
benzoyloxynortropane	I-IUPAC
and	O
other	O
analogues	O
with	O
larger	O
acyl	O
moieties	O
was	O
little	O
affected	O
by	O
N	O
-	O
methylation	O
or	O
in	O
some	O
cases	O
was	O
increased	O
.	O
Furthermore	O
,	O
(	B-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolyl	I-IUPAC
]	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
2	O
-	O
Fu	O
-	O
AMPA	O
,	O
7f	O
)	O
and	O
its	O
5	B-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furyl	I-IUPAC
derivative	B-MODIFIER
(	O
7g	O
)	O
were	O
synthesized	O
,	O
and	O
(	O
S	O
)	O
-	O
2	O
-	O
Fu	O
-	O
AMPA	O
(	O
8	O
)	O
and	O
(	O
R	O
)	O
-	O
2	O
-	O
Fu	O
-	O
AMPA	O
(	O
9	O
)	O
were	O
prepared	O
by	O
semipreparative	O
chiral	O
HPLC	O
resolution	O
of	O
7f	O
.	O
In	O
vitro	O
quantitative	O
autoradiography	O
determined	O
that	O
3	O
,	O
7	O
,	O
and	O
8	O
had	O
potent	O
binding	O
affinities	O
(	O
K	O
(	O
i	O
)	O
=	O
0.07-0.19	O
nM	O
)	O
for	O
PBR	O
in	O
the	O
rat	O
brain	O
.	O
The	O
alkyl	B-PARTIUPAC
substituent	B-MODIFIER
on	O
this	O
side	O
chain	O
can	O
be	O
methyl	B-PARTIUPAC
,	O
ethyl	B-PARTIUPAC
,	O
or	O
cyclopropyl	B-PARTIUPAC
.	O
Nevertheless	O
,	O
these	O
21	O
-	O
functionalized	O
derivatives	O
of	O
(	B-IUPAC
9R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
erythromycylamine	I-IUPAC
provide	O
an	O
entry	O
into	O
novel	O
analogues	O
of	O
the	O
important	O
macrolide	O
antibiotic	O
erythromycin	O
.	O
The	O
pyrrolidinyl	B-IUPAC
(	O
or	O
N	B-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dialkyl	I-IUPAC
)	I-IUPAC
,	I-IUPAC
ethylenediamine	I-IUPAC
,	O
N	B-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
,	O
and	O
phenylethyl	B-IUPAC
portions	B-MODIFIER
of	O
this	O
sigma	O
receptor	O
pharmacophore	O
were	O
restricted	O
by	O
its	O
incorporation	O
into	O
1,2	B-IUPAC
-	I-IUPAC
cyclohexanediamine	I-IUPAC
-	O
,	O
pyrrolidine	B-IUPAC
-	O
,	O
piperidine	B-PARTIUPAC
-	O
,	O
homopiperidine	B-PARTIUPAC
-	O
,	O
and	O
tetrahydroisoquinoline	B-IUPAC
-	O
containing	B-MODIFIER
ligands	I-MODIFIER
.	O
Accessible	O
conformers	O
of	O
each	O
molecule	O
were	O
identified	O
by	O
using	O
the	O
method	O
of	O
molecular	O
mechanics	O
as	O
encoded	O
in	O
the	O
MMP2	O
(	O
85	O
)	O
program	O
.	O
Both	O
di	O
-	O
and	O
triacetylated	O
derivatives	O
of	O
6	B-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
acetoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylbutyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxoethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
acetylamino	I-IUPAC
)	I-IUPAC
butan	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
olide	I-IUPAC
(	O
8	O
)	O
and	O
4	B-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
acetoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
acetoxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylbutyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxoethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
acetylamino	I-IUPAC
)	I-IUPAC
butan	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
olide	I-IUPAC
(	O
9	O
)	O
,	O
were	O
inactive	O
.	O
The	O
dithionite	O
reduction	O
product	O
,	O
7,8	B-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
thiohomofolic	I-IUPAC
acid	I-IUPAC
,	O
was	O
able	O
to	O
function	O
as	O
a	O
substrate	O
of	O
L	O
.	O
Among	O
the	O
four	O
isomers	O
of	O
3	O
,	O
the	O
(	O
aR	O
,	O
S	O
)	O
-	O
enantiomer	O
(	O
3a	O
-	O
A	O
)	O
exhibited	O
the	O
most	O
potent	O
antagonistic	O
activities	O
with	O
an	O
IC50	O
value	O
of	O
0.80	O
nM	O
(	O
in	O
vitro	O
inhibition	O
of	O
[	O
125I	O
]	O
BH	O
-	O
SP	O
binding	O
in	O
human	O
IM	O
-	O
9	O
cells	O
)	O
and	O
ED50	O
values	O
of	O
9.3	O
micrograms	O
/	O
kg	O
(	O
iv	O
)	O
and	O
67.7	O
micrograms	O
/	O
kg	O
(	O
po	O
)	O
(	O
in	O
vivo	O
inhibition	O
of	O
capsaicin	O
-	O
induced	O
plasma	O
extravasation	O
in	O
guinea	O
pig	O
trachea	O
)	O
,	O
while	O
the	O
activity	O
of	O
the	O
(	O
aS	O
,	O
R	O
)	O
-	O
enantiomer	O
(	O
3b	O
-	O
B	O
)	O
was	O
the	O
weakest	O
with	O
an	O
IC50	O
value	O
of	O
620	O
nM	O
.	O
Some	O
novel	O
6	B-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	O
substituted	B-MODIFIER
-	O
1,4	B-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxoquinoline	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acids	I-IUPAC
have	O
been	O
prepared	O
.	O
Related	O
pyran	B-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
,	O
pyran	B-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
,	O
and	O
thiopyran	B-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
showed	O
similar	O
IC50	O
values	O
against	O
DNA	O
-	O
PK	O
,	O
whereas	O
the	O
pyridin	B-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
system	B-MODIFIER
proved	O
,	O
in	O
general	O
,	O
ineffective	O
at	O
inhibiting	O
DNA	O
-	O
PK	O
.	O
A	O
series	O
of	O
straight	O
-	O
chain	O
N5	B-IUPAC
-	I-IUPAC
aminoalkylacyl	I-IUPAC
derivatives	B-MODIFIER
demonstrated	O
that	O
for	O
A2B	O
receptors	O
the	O
optimal	O
chain	O
length	O
occurs	O
with	O
three	O
methylene	O
groups	O
,	O
i.e.	O
,	O
the	O
N5	B-IUPAC
-	I-IUPAC
gamma	I-IUPAC
-	I-IUPAC
aminobutyryl	I-IUPAC
derivative	B-MODIFIER
27	O
which	O
had	O
a	O
pA2	O
value	O
of	O
8.0	O
but	O
was	O
not	O
selective	O
for	O
A2B	O
receptors	O
.	O
Preliminary	O
biological	O
studies	O
showed	O
that	O
7	B-IUPAC
-	I-IUPAC
methyl	I-IUPAC
and	O
5,7	B-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
analogues	B-MODIFIER
(	O
1b	O
and	O
1e	O
)	O
were	O
less	O
active	O
than	O
methotrexate	O
against	O
human	O
leukemic	O
HL	O
-	O
60	O
and	O
murine	O
L	O
-	O
1210	O
cells	O
in	O
tissue	O
culture	O
.	O
These	O
compounds	O
were	O
used	O
as	O
intermediates	O
for	O
the	O
synthesis	O
of	O
a	O
new	O
series	O
of	O
water	O
-	O
soluble	O
compounds	O
derived	O
from	O
3	B-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dialkylamino	I-IUPAC
)	I-IUPAC
alkyl	I-IUPAC
[	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
quinoxalinecarbonitrile	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
oxides	I-IUPAC
10a	O
-	O
i	O
and	O
11a	O
-	O
i	O
.	O
The	O
synthesis	O
of	O
several	O
analogues	O
of	O
(	B-IUPAC
8R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
erythro	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3,6,7,8	I-IUPAC
-	I-IUPAC
tetrahydroimidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,3	I-IUPAC
]	I-IUPAC
diazepin	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
ol	I-IUPAC
(	O
pentostatin	O
,	O
1a	O
)	O
is	O
described	O
.	O
Side	O
chain	O
mobility	O
is	O
analyzed	O
with	O
time	O
-	O
dependent	O
distance	O
restraints	O
.	O
The	O
newly	O
synthesized	O
radioactive	O
inhibitors	O
were	O
utilized	O
to	O
study	O
ex	O
vivo	O
biodistribution	O
in	O
mice	O
,	O
and	O
the	O
tumor	O
-	O
to	O
-	O
blood	O
ratio	O
of	O
tissue	O
uptake	O
of	O
[	O
(	O
131	O
)	O
I	O
]	O
IBG	O
and	O
[	O
(	O
131	O
)	O
I	O
]	O
IBGG	O
was	O
determined	O
to	O
be	O
0.24	O
and	O
0.76	O
after	O
0.5	O
h	O
,	O
respectively	O
.	O
The	O
4	B-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxyalkyl	I-IUPAC
)	I-IUPAC
estrogens	I-IUPAC
were	O
prepared	O
by	O
oxidative	O
hydroboration	O
of	O
4	B-IUPAC
-	I-IUPAC
alkenylestradiols	I-IUPAC
.	O
Of	O
the	O
investigated	O
compounds	O
,	O
the	O
most	O
active	O
was	O
2,5,9,11	B-IUPAC
-	I-IUPAC
tetramethyl	I-IUPAC
-	I-IUPAC
5H	I-IUPAC
-	I-IUPAC
indolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
quinoline	I-IUPAC
,	O
a	O
compound	O
bearing	O
the	O
highest	O
number	O
of	O
symmetrically	O
distributed	O
methyl	B-IUPAC
groups	B-MODIFIER
.	O
A	O
series	O
of	O
sulfonyl	B-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
hydroxyguanidine	I-IUPAC
derivatives	B-MODIFIER
was	O
designed	O
and	O
synthesized	O
for	O
cytotoxic	O
evaluation	O
as	O
potential	O
anticancer	O
agents	O
on	O
the	O
basis	O
of	O
the	O
lead	O
compound	O
LY	O
-	O
181984	O
.	O
Preferred	O
compounds	O
are	O
N	B-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
azido	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chloropyridin	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
)	I-IUPAC
with	O
2	B-IUPAC
-	I-IUPAC
iminothiazoline	I-IUPAC
for	O
alpha4beta2	O
(	O
K	O
(	O
i	O
)	O
=	O
0.47	O
nM	O
)	O
and	O
with	O
2	B-IUPAC
-	I-IUPAC
nitroiminothiazoline	I-IUPAC
or	O
2	B-IUPAC
-	I-IUPAC
nitromethyleneimidazolidine	I-IUPAC
for	O
Drosophila	O
(	O
K	O
(	O
i	O
)	O
=	O
0.72-3.9	O
nM	O
)	O
.	O
The	O
42	O
platinum	O
(	O
II	O
)	O
complexes	O
having	O
a	O
seven	O
-	O
membered	O
ring	O
structure	O
in	O
this	O
series	O
have	O
been	O
prepared	O
and	O
characterized	O
by	O
1H	O
NMR	O
,	O
13C	O
NMR	O
,	O
IR	O
,	O
FAB	O
-	O
MS	O
,	O
and	O
elemental	O
analysis	O
.	O
Structure	O
-	O
activity	O
studies	O
using	O
potassium	O
-	O
depolarized	O
rabbit	O
aorta	O
show	O
that	O
ortho	B-IUPAC
,	O
meta	B-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
aryl	B-IUPAC
derivatives	B-MODIFIER
are	O
more	O
potent	O
than	O
either	O
ortho	O
-	O
or	O
meta	O
-	O
monosubstituted	O
compounds	O
.	O
Consequently	O
,	O
the	O
presence	O
of	O
the	O
heteroatom	O
does	O
not	O
eradicate	O
the	O
activity	O
of	O
the	O
heteroarotinoids	O
and	O
thus	O
they	O
may	O
have	O
potential	O
as	O
chemotherapeutic	O
agents	O
.	O
The	O
trans	B-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
analogs	B-MODIFIER
showed	O
selective	O
5	O
-	O
HT1A	O
receptor	O
activity	O
in	O
vitro	O
but	O
displayed	O
mixed	O
5	O
-	O
HT1A	O
and	O
D2	O
agonist	O
properties	O
in	O
vivo	O
.	O
The	O
requisite	O
8	B-IUPAC
-	I-IUPAC
hydroxyquinazolinones	I-IUPAC
(	O
6	O
,	O
35-39	O
)	O
were	O
synthesized	O
by	O
demethylation	O
of	O
the	O
corresponding	O
8	B-IUPAC
-	I-IUPAC
methoxyquinazolinones	I-IUPAC
with	O
BBr3	O
.	O
The	O
in	O
vitro	O
antitumor	O
activity	O
in	O
ovarian	O
cancer	O
cells	O
(	O
CH1	O
)	O
has	O
been	O
determined	O
by	O
means	O
of	O
the	O
MTT	O
assay	O
.	O
Modification	O
of	O
the	O
benzodiazepine	O
(	O
BZ	O
)	O
receptor	O
binding	O
template	O
2	B-IUPAC
-	I-IUPAC
aryl	I-IUPAC
[	I-IUPAC
1,2,4	I-IUPAC
]	I-IUPAC
triazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
quinazolin	I-IUPAC
-	I-IUPAC
5	I-IUPAC
(	I-IUPAC
6H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
by	O
replacement	O
of	O
the	O
annelated	O
benzene	O
ring	O
with	O
various	O
alicyclic	O
and	O
heterocyclic	O
moieties	O
led	O
to	O
novel	O
structures	O
with	O
potent	O
BZ	O
receptor	O
binding	O
affinity	O
.	O
To	O
shed	O
light	O
on	O
the	O
mechanism	O
(	O
s	O
)	O
underlying	O
this	O
quite	O
enigmatic	O
pharmacological	O
profile	O
of	O
4	O
-	O
AHCP	O
,	O
we	O
have	O
now	O
developed	O
a	O
synthesis	O
of	O
(	O
S	O
)	O
-	O
4	O
-	O
AHCP	O
(	O
6	O
)	O
and	O
(	O
R	O
)	O
-	O
4	O
-	O
AHCP	O
(	O
7	O
)	O
.	O
Triamines	O
11	O
and	O
13	O
[	O
Ki	O
(	O
sigma	O
-	O
2	O
)	O
/	O
K	O
(	O
i	O
)	O
(	O
sigma	O
-	O
1	O
)	O
=	O
0.19	O
and	O
0.10	O
,	O
respectively	O
]	O
containing	O
the	O
N	O
-	O
N	O
-	O
N	O
-	O
Ar	O
spacings	O
3-3-2	O
and	O
4-4-2	O
,	O
proved	O
to	O
be	O
the	O
most	O
sigma	O
-	O
2	O
subtype	O
selective	O
of	O
the	O
15	O
polyamines	O
examined	O
in	O
this	O
study	O
.	O
These	O
results	O
make	O
meta	B-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
2	B-IUPAC
-	I-IUPAC
phenylhistamines	I-IUPAC
,	O
especially	O
2	B-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
3	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
trifluoromethyl	I-PARTIUPAC
)	I-PARTIUPAC
phenyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
bromophenyl	I-IUPAC
)	I-IUPAC
histamine	I-IUPAC
(	O
39	O
and	O
35	O
,	O
respectively	O
)	O
valuable	O
experimental	O
tools	O
for	O
the	O
selective	O
stimulation	O
of	O
histamine	O
H1	O
receptors	O
and	O
the	O
study	O
of	O
H1	O
receptor	O
-	O
mediated	O
functions	O
.	O
Within	O
the	O
group	O
of	O
heterocyclic	O
analogs	O
,	O
3	B-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thienyl	I-IUPAC
)	I-IUPAC
alanine	I-IUPAC
proved	O
to	O
be	O
the	O
best	O
modification	O
,	O
displaying	O
a	O
delta	O
receptor	O
Ki	O
of	O
1.38	O
nM	O
,	O
while	O
the	O
polar	O
histidine	O
analog	O
suffered	O
the	O
greatest	O
loss	O
in	O
delta	O
binding	O
(	O
Ki	O
=	O
317	O
)	O
.	O
We	O
are	O
able	O
to	O
rationalize	O
the	O
observed	O
selectivities	O
by	O
comparing	O
the	O
docking	O
of	O
4	O
and	O
6	O
to	O
subtype	O
constructs	O
,	O
i.e.	O
,	O
a	O
crystal	O
structure	O
of	O
the	O
extracellular	O
binding	O
domain	O
of	O
GluR2	O
and	O
a	O
homology	O
model	O
of	O
GluR5	O
.	O
The	O
antiviral	O
activity	O
of	O
both	O
compounds	O
was	O
well	O
separated	O
from	O
cytotoxicity	O
in	O
KB	O
,	O
HFF	O
,	O
and	O
L1210	O
cells	O
.	O
Six	O
of	O
the	O
eight	O
diamidines	O
gave	O
in	O
vitro	O
IC	O
(	O
50	O
)	O
values	O
of	O
63	O
nM	O
or	O
less	O
vs	O
T	O
.	O
Active	O
1,4	B-IUPAC
-	I-IUPAC
dihydronaphthoquinone	I-IUPAC
acetates	I-IUPAC
(	O
IC50	O
less	O
than	O
20	O
microM	O
)	O
were	O
evaluated	O
in	O
an	O
ex	O
vivo	O
LTB4	O
inhibition	O
assay	O
.	O
carinii	O
DHFR	O
,	O
2,4	B-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
3'	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
trimethoxyanilino	I-IUPAC
)	I-IUPAC
methy	I-IUPAC
l	I-IUPAC
]	I-IUPAC
quinazoline	I-IUPAC
(	O
10	O
)	O
had	O
an	O
IC50	O
of	O
0.012	O
microM	O
and	O
was	O
slightly	O
more	O
potent	O
than	O
TMQ	O
and	O
PTX	O
.	O
K	O
(	O
i	O
)	O
values	O
for	O
spermidine	O
uptake	O
were	O
also	O
determined	O
in	O
L1210	O
cells	O
.	O
;	O
Wilson	O
,	O
I	O
.	O
The	O
compound	O
2	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolyl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
3a	O
)	O
(	O
IC	O
(	O
50	O
)	O
=	O
0.11	O
microM	O
;	O
EC	O
(	O
50	O
)	O
=	O
1.2	O
microM	O
)	O
,	O
which	O
is	O
a	O
regioisostere	O
of	O
2	O
with	O
a	O
methoxy	O
group	O
substituted	O
for	O
the	O
methyl	B-IUPAC
group	B-MODIFIER
,	O
was	O
approximately	O
equipotent	O
with	O
2	O
(	O
IC	O
(	O
50	O
)	O
=	O
0.020	O
microM	O
;	O
EC	O
(	O
50	O
)	O
=	O
1.0	O
microM	O
)	O
as	O
an	O
inhibitor	O
of	O
[	O
(	O
3	O
)	O
H	O
]	O
AMPA	O
binding	O
and	O
as	O
an	O
AMPA	O
agonist	O
,	O
respectively	O
,	O
whereas	O
the	O
corresponding	O
3	O
-	O
ethoxy	O
analogue	O
3b	O
(	O
IC	O
(	O
50	O
)	O
=	O
1.0	O
microM	O
;	O
EC	O
(	O
50	O
)	O
=	O
4.8	O
microM	O
)	O
was	O
slightly	O
weaker	O
.	O
These	O
data	O
for	O
the	O
heteroarotinoid	O
1b	O
revealed	O
that	O
the	O
two	O
aryl	O
ring	O
systems	O
were	O
nearly	O
perpendicular	O
in	O
each	O
of	O
the	O
two	O
molecules	O
present	O
in	O
the	O
unit	O
cell	O
(	O
86.37	O
degrees	O
and	O
84.17	O
degrees	O
,	O
respectively	O
)	O
.	O
In	O
one	O
of	O
the	O
biological	O
tests	O
a	O
significant	O
difference	O
was	O
found	O
between	O
8	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydroisoquinoline	I-IUPAC
(	O
nomifensine	O
)	O
and	O
the	O
new	O
compounds	O
synthesized	O
.	O
The	O
7,8	B-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
(	O
18a	O
)	O
and	O
7,8	B-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
(	O
18b	O
)	O
analogs	B-MODIFIER
are	O
the	O
most	O
potent	O
THHBADs	O
prepared	O
and	O
have	O
apparent	O
antagonist	O
dissociation	O
constants	O
(	O
Kb	O
values	O
)	O
of	O
0.0041	O
and	O
0.0028	O
microM	O
,	O
respectively	O
,	O
for	O
NMDA	O
receptors	O
and	O
0.51	O
and	O
0.72	O
microM	O
,	O
respectively	O
,	O
for	O
AMPA	O
receptors	O
.	O
The	O
(	B-IUPAC
propargyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
acyclonucleoside	I-IUPAC
analogues	B-MODIFIER
of	O
6	B-IUPAC
-	I-IUPAC
chloropurine	I-IUPAC
,	O
adenine	B-IUPAC
,	O
6	B-IUPAC
-	I-IUPAC
methoxypurine	I-IUPAC
,	O
hypoxanthine	B-IUPAC
,	O
6	B-IUPAC
-	I-IUPAC
mercaptopurine	I-IUPAC
,	O
and	O
azathioprine	B-IUPAC
have	O
been	O
prepared	O
.	O
As	O
part	O
of	O
a	O
search	O
for	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
inhibitors	O
combining	O
the	O
high	O
potency	O
of	O
piritrexim	O
(	O
PTX	O
)	O
with	O
the	O
high	O
antiparasitic	O
vs	O
mammalian	O
selectivity	O
of	O
trimethoprim	O
(	O
TMP	O
)	O
,	O
the	O
heretofore	O
undescribed	O
2,4	B-PARTIUPAC
-	I-PARTIUPAC
diamino	I-PARTIUPAC
-	I-PARTIUPAC
6	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
2'	B-MODIFIER
,	I-MODIFIER
5'	I-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
benzyl	B-PARTIUPAC
)	I-PARTIUPAC
pyrido	I-PARTIUPAC
[	I-PARTIUPAC
2,3	I-PARTIUPAC
-	I-PARTIUPAC
d	I-PARTIUPAC
]	I-PARTIUPAC
pyrimidines	I-PARTIUPAC
6-14	O
with	O
O	B-IUPAC
-	I-IUPAC
(	I-IUPAC
omega	I-IUPAC
-	I-IUPAC
carboxyalkyl	I-IUPAC
)	I-IUPAC
or	O
omega	B-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
alkynyl	I-IUPAC
groups	B-MODIFIER
on	O
the	O
benzyl	B-IUPAC
moiety	B-MODIFIER
were	O
synthesized	O
and	O
tested	O
against	O
Pneumocystis	O
carinii	O
,	O
Toxoplasma	O
gondii	O
,	O
and	O
Mycobacterium	O
avium	O
DHFR	O
vs	O
rat	O
DHFR	O
.	O
1	B-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Dialkylamino	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5H	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
4,3	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
benzo	I-IUPAC
[	I-IUPAC
e	I-IUPAC
]	I-IUPAC
indoles	I-IUPAC
appeared	O
as	O
a	O
promising	O
new	O
class	O
of	O
antineoplastic	O
agents	O
.	O
A	O
series	O
of	O
N	B-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
pyridinyl	I-IUPAC
)	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
3	B-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
propenyl	B-IUPAC
carboxamide	I-IUPAC
derivatives	B-MODIFIER
bearing	O
an	O
unsaturated	O
bicyclic	O
moiety	O
in	O
the	O
3	O
-	O
position	O
was	O
prepared	O
and	O
evaluated	O
for	O
PAF	O
(	O
platelet	O
activating	O
factor	O
)	O
antagonist	O
activity	O
.	O
The	O
5	B-IUPAC
-	I-IUPAC
H	I-IUPAC
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
indanylamide	I-IUPAC
7a	O
displayed	O
a	O
lower	O
affinity	O
(	O
K	O
(	O
i	O
)	O
675	O
nM	O
)	O
.	O
Structure	O
-	O
activity	O
studies	O
showed	O
that	O
the	O
C	O
-	O
5	O
substituent	O
(	O
I	O
,	O
Br	O
,	O
Cl	O
)	O
was	O
a	O
determinant	O
of	O
anti	O
-	O
HIV	O
-	O
1	O
activity	O
where	O
the	O
potency	O
order	O
was	O
I	O
&	O
gt	O
;	O
or	O
=	O
Br	O
&	O
gt	O
;	O
Cl	O
.	O
Radiolabeled	O
[	O
125I	O
]	O
-	O
8	O
was	O
prepared	O
from	O
the	O
corresponding	O
tri	B-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
butyltin	I-IUPAC
precursor	O
via	O
an	O
oxidative	O
iododestannylation	O
reaction	O
with	O
sodium	O
[	O
125I	O
]	O
iodide	O
.	O
Either	O
the	O
bond	O
between	O
the	O
inhibitor	O
and	O
the	O
enzyme	O
did	O
not	O
withstand	O
the	O
hydrolytic	O
conditions	O
and	O
/	O
or	O
there	O
was	O
less	O
than	O
10%	O
decrease	O
in	O
the	O
amino	O
acids	O
with	O
nucleophilic	O
side	O
chains	O
upon	O
inactivation	O
.	O
Compounds	O
were	O
assayed	O
in	O
vitro	O
in	O
a	O
PAF	O
-	O
binding	O
assay	O
employing	O
washed	O
,	O
whole	O
dog	O
platelets	O
as	O
the	O
receptor	O
source	O
and	O
in	O
vivo	O
after	O
intravenous	O
or	O
oral	O
administration	O
for	O
their	O
ability	O
to	O
prevent	O
PAF	O
-	O
induced	O
bronchoconstriction	O
in	O
guinea	O
pigs	O
.	O
The	O
2	B-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
1	B-IUPAC
-	I-IUPAC
aza	I-IUPAC
-	I-IUPAC
5	I-IUPAC
[	I-IUPAC
H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
phenanthridin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
were	O
designed	O
to	O
improve	O
the	O
solubility	O
and	O
pharmacokinetic	O
profiles	O
for	O
this	O
series	O
of	O
PARP	O
-	O
1	O
inhibitors	O
.	O
Enzyme	O
-	O
mediated	O
addition	O
of	O
water	O
across	O
the	O
5,6	O
-	O
double	O
bond	O
could	O
generate	O
electrophilic	O
acyl	O
halide	O
or	O
alpha	B-IUPAC
-	I-IUPAC
halo	I-IUPAC
ketone	I-IUPAC
species	O
that	O
could	O
undergo	O
nucleophilic	O
attack	O
by	O
proximal	O
groups	O
on	O
the	O
enzyme	O
.	O
No	O
correlation	O
was	O
found	O
between	O
retention	O
times	O
and	O
antagonist	O
potency	O
or	O
duration	O
of	O
action	O
.	O
From	O
these	O
studies	O
,	O
an	O
initial	O
rate	O
constant	O
,	O
Ki	O
,	O
for	O
7d	O
and	O
7n	O
was	O
found	O
to	O
be	O
345	O
and	O
465	O
nM	O
,	O
respectively	O
.	O
Among	O
them	O
,	O
we	O
have	O
found	O
that	O
methyl	B-IUPAC
2	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
3	I-IUPAC
,	I-IUPAC
12	I-IUPAC
-	I-IUPAC
dioxooleana	I-IUPAC
-	I-IUPAC
1,9	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
-	I-IUPAC
dien	I-IUPAC
-	I-IUPAC
28	I-IUPAC
-	I-IUPAC
oate	I-IUPAC
(	O
25	O
)	O
,	O
2	B-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
3,12	I-IUPAC
-	I-IUPAC
dioxooleana	I-IUPAC
-	I-IUPAC
1,9	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
-	I-IUPAC
dien	I-IUPAC
-	I-IUPAC
28	I-IUPAC
-	I-IUPAC
oic	I-IUPAC
acid	I-IUPAC
(	O
CDDO	O
)	O
(	O
26	O
)	O
,	O
and	O
methyl	B-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
3,12	I-IUPAC
-	I-IUPAC
dioxooleana	I-IUPAC
-	I-IUPAC
1,9	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
-	I-IUPAC
dien	I-IUPAC
-	I-IUPAC
28	I-IUPAC
-	I-IUPAC
oate	I-IUPAC
(	O
29	O
)	O
have	O
extremely	O
high	O
potency	O
(	O
IC	O
(	O
50	O
)	O
=	O
0.1	O
nM	O
level	O
)	O
.	O
When	O
tested	O
iv	O
,	O
activity	O
was	O
found	O
in	O
the	O
N	B-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
m	I-IUPAC
-	I-IUPAC
phenylene	I-IUPAC
)	I-IUPAC
dioxamic	I-IUPAC
acids	I-IUPAC
up	O
to	O
2500	O
times	O
that	O
shown	O
by	O
disodium	O
cromoglycate	O
[	O
50%	O
inhibition	O
at	O
0.001	O
mg	O
/	O
kg	O
for	O
N	B-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
m	I-IUPAC
-	I-IUPAC
phenylene	I-IUPAC
)	I-IUPAC
dioxamic	I-IUPAC
acid	I-IUPAC
(	O
compound	O
61	O
)	O
]	O
.	O
The	O
5	B-IUPAC
-	I-IUPAC
halo	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
5,6	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
derivatives	B-MODIFIER
of	O
AZT	O
are	O
more	O
lipophilic	O
(	O
P	O
=	O
3.3-18.8	O
range	O
)	O
than	O
the	O
parent	O
compound	O
AZT	O
(	O
P	O
=	O
1.29	O
)	O
.	O
This	O
trend	O
was	O
consistent	O
with	O
the	O
published	O
literature	O
on	O
the	O
corresponding	O
DHFR	O
inhibitors	O
with	O
a	O
glutamate	O
side	O
chain	O
.	O
4	B-IUPAC
-	I-IUPAC
Aminopyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
was	O
converted	O
into	O
the	O
desired	O
intermediate	O
,	O
ethyl	B-IUPAC
pyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carbamate	I-IUPAC
(	O
2	O
)	O
.	O
All	O
peptide	O
bonds	O
are	O
found	O
to	O
be	O
trans	O
.	O
Isopycnic	O
centrifugation	O
of	O
32P	O
-	O
labeled	O
DNA	O
indicated	O
that	O
if	O
0.5	O
or	O
2	O
microM	O
TFPe	O
-	O
dUrd	O
was	O
present	O
for	O
0-6	O
h	O
postinfection	O
,	O
viral	O
DNA	O
synthesis	O
was	O
reduced	O
by	O
ca.	O
50	O
and	O
85%	O
,	O
respectively	O
;	O
concomitantly	O
,	O
a	O
new	O
DNA	O
band	O
appeared	O
at	O
lower	O
density	O
than	O
normal	O
cellular	O
or	O
viral	O
DNA	O
.	O
3'	B-IUPAC
-	I-IUPAC
C	I-IUPAC
-	I-IUPAC
Methyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxythymidine	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
triphosphate	I-IUPAC
was	O
synthesized	O
and	O
proved	O
to	O
be	O
a	O
competitive	O
inhibitor	O
,	O
with	O
respect	O
to	O
dTTP	O
,	O
of	O
a	O
number	O
of	O
DNA	O
polymerases	O
,	O
including	O
the	O
reverse	O
transcriptases	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
and	O
avian	O
myeloblastosis	O
virus	O
(	O
AMV	O
)	O
.	O
All	O
these	O
peptides	O
share	O
a	O
common	O
rigid	O
tripeptide	O
cycle	O
with	O
a	O
single	O
energetically	O
preferred	O
backbone	O
conformation	O
and	O
three	O
different	O
conformers	O
of	O
the	O
D	O
-	O
Cys	O
,	O
D	O
-	O
Pen	O
disulfide	O
bridge	O
,	O
two	O
of	O
which	O
are	O
observed	O
in	O
the	O
solid	O
state	O
and	O
in	O
aqueous	O
solution	O
,	O
as	O
previously	O
determined	O
from	O
X	O
-	O
ray	O
crystallography	O
and	O
1H	O
NMR	O
spectroscopy	O
data	O
(	O
Lomize	O
,	O
A	O
;	O
et	O
al.	O
J	O
.	O
The	O
only	O
relevant	O
difference	O
between	O
the	O
active	O
and	O
the	O
inactive	O
compounds	O
detected	O
thus	O
far	O
is	O
the	O
rotational	O
barrier	O
of	O
the	O
phenyl	O
in	O
the	O
5	O
-	O
position	O
.	O
Formylation	O
of	O
amines	O
10-27	O
gave	O
17	B-IUPAC
beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
alkylformamides	I-IUPAC
)	I-IUPAC
28-41	O
;	O
however	O
,	O
acylation	O
afforded	O
17	B-IUPAC
beta	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
/	I-IUPAC
aryl	I-IUPAC
)	I-IUPAC
alkyl	I-IUPAC
/	I-IUPAC
arylamides	I-IUPAC
]	I-IUPAC
42-53	O
.	O
The	O
anticancer	O
activity	O
of	O
pyrrolidinones	O
16a	O
-	O
e	O
and	O
3	B-IUPAC
-	I-IUPAC
alkylidenefuranones	I-IUPAC
18a	O
-	O
c	O
was	O
much	O
weaker	O
than	O
that	O
of	O
furanones	O
13a	O
-	O
e	O
.	O
These	O
compounds	O
were	O
able	O
to	O
displace	O
the	O
highly	O
selective	O
sigma	O
receptor	O
probe	O
[	B-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pentazocine	I-IUPAC
from	O
guinea	O
pig	O
brain	O
homogenates	O
with	O
Ki	O
values	O
ranging	O
from	O
125	O
to	O
9170	O
nM	O
.	O
Several	O
8	B-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
O6	B-IUPAC
-	I-IUPAC
benzylguanines	I-IUPAC
,	O
2	B-MODIFIER
-	I-MODIFIER
and	O
/	O
or	O
8	B-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
6	B-IUPAC
-	I-IUPAC
(	I-IUPAC
benzyloxy	I-IUPAC
)	I-IUPAC
purines	I-IUPAC
,	O
substituted	B-MODIFIER
6	B-IUPAC
(	I-IUPAC
4	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
benzyloxy	I-IUPAC
)	I-IUPAC
pyrimidines	I-IUPAC
,	O
and	O
a	O
6	B-IUPAC
-	I-IUPAC
(	I-IUPAC
benzyloxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
s	I-IUPAC
-	I-IUPAC
triazine	I-IUPAC
were	O
tested	O
for	O
their	O
ability	O
to	O
inactivate	O
the	O
human	O
DNA	O
repair	O
protein	O
,	O
O6	B-IUPAC
-	I-IUPAC
alkylguanine	I-IUPAC
-	O
DNA	O
alkyltransferase	O
(	O
AGT	O
,	O
alkyltransferase	O
)	O
.	O
However	O
,	O
contrary	O
to	O
expectations	O
based	O
on	O
the	O
aforementioned	O
F2Pmp	O
work	O
,	O
incorporation	O
of	O
this	O
putative	O
pTyr	O
mimetic	O
into	O
the	O
pseudo	O
-	O
dipeptide	O
,	O
N	B-IUPAC
-	I-IUPAC
[	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
carboxymethyloxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthoyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
glutamic	I-IUPAC
acid	I-IUPAC
,	O
resulted	O
in	O
a	O
substantial	O
loss	O
of	O
binding	O
affinity	O
.	O
Neuroprotective	O
properties	O
assessed	O
after	O
postischemic	O
dosing	O
in	O
a	O
Mongolian	O
gerbil	O
severe	O
temporary	O
forebrain	O
ischemia	O
paradigm	O
,	O
using	O
hippocampal	O
CA1	O
damage	O
endpoints	O
,	O
and	O
the	O
efficacy	O
of	O
these	O
agonists	O
in	O
an	O
A	O
(	O
1	O
)	O
functional	O
assay	O
show	O
similarities	O
to	O
some	O
reference	O
adenosine	O
agonists	O
.	O
The	O
disodium	O
salts	O
of	O
the	O
phosphate	O
prodrugs	O
exhibited	O
high	O
water	O
solubility	O
(	B-IUPAC
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
m	I-IUPAC
-	I-IUPAC
methoxystyryl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
phosphatylpropyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propargylxan	I-IUPAC
thine	I-IUPAC
disodium	I-IUPAC
salt	I-IUPAC
,	O
9b	O
:	O
17	O
mM	O
,	O
9	O
mg	O
/	O
mL	O
)	O
.	O
Treatment	O
of	O
4b	O
with	O
benzaldehyde	B-IUPAC
gave	O
1	B-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
styryltetrahydropyrimido	I-IUPAC
[	I-IUPAC
5,4	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
quinoline	I-IUPAC
(	O
5	O
)	O
.	O
A	O
prodrug	O
of	O
N1	B-IUPAC
-	I-IUPAC
ethylchlorpropamide	I-IUPAC
,	O
viz	O
.	O
A	O
series	O
of	O
new	O
dipeptidyl	O
alpha	O
-	O
keto	O
amides	O
of	O
the	O
general	O
structure	O
R1	O
-	O
L	O
-	O
Leu	O
-	O
D	O
,	O
L	O
-	O
AA	O
-	O
CONH	O
-	O
R2	O
were	O
synthesized	O
and	O
evaluated	O
as	O
inhibitors	O
for	O
the	O
cysteine	O
proteases	O
calpain	O
I	O
,	O
calpain	O
II	O
,	O
and	O
cathepsin	O
B	O
.	O
Steric	O
and	O
electrostatic	O
requirements	O
at	O
position	O
6	O
of	O
[	O
Nle	O
(	O
10	O
)	O
]	O
NKA	O
(	O
4-10	O
)	O
,	O
a	O
full	O
agonist	O
of	O
NK	O
-	O
2	O
receptors	O
,	O
for	O
molecular	O
recognition	O
by	O
the	O
receptor	O
were	O
studied	O
.	O
HBr	O
and	O
its	O
analogs	O
is	O
different	O
from	O
that	O
of	O
compound	O
10	O
as	O
indicated	O
by	O
the	O
mutual	O
exclusivity	O
with	O
other	O
inhibitors	O
and	O
the	O
relative	O
inhibition	O
of	O
the	O
activity	O
with	O
various	O
electron	O
acceptors	O
.	O
)	O
demonstrated	O
that	O
substratelike	O
turnover	O
was	O
proceeding	O
at	O
considerably	O
slower	O
rates	O
than	O
for	O
the	O
corresponding	O
true	O
substrates	O
and	O
with	O
rate	O
-	O
limiting	O
deacylation	O
of	O
the	O
acyl	O
-	O
enzyme	O
.	O
The	O
synthesis	O
of	O
5,11	B-IUPAC
-	I-IUPAC
methenyltetrahydrohomofolate	I-IUPAC
was	O
accomplished	O
by	O
treatment	O
of	O
tetrahydrohomofolate	O
(	O
H4homofolate	O
)	O
with	O
triethyl	O
orthoformate	O
in	O
glacial	O
acetic	O
acid	O
.	O
3'	B-IUPAC
-	I-IUPAC
C	I-IUPAC
-	I-IUPAC
Methyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyluridine	I-IUPAC
did	O
not	O
suppress	O
HIV	O
-	O
1	O
replication	O
in	O
MT	O
-	O
4	O
cells	O
at	O
500	O
microM	O
while	O
its	O
5'	B-IUPAC
-	I-IUPAC
phosphite	I-IUPAC
derivative	B-MODIFIER
exhibited	O
modest	O
anti	O
-	O
HIV	O
-	O
1	O
activity	O
.	O
Key	O
steps	O
in	O
the	O
sequence	O
are	O
the	O
peptide	O
coupling	O
of	O
N	B-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
benzyloxy	I-IUPAC
)	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
methylamino	I-IUPAC
]	I-IUPAC
benzoyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamic	I-IUPAC
acid	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
ester	I-IUPAC
(	O
5	O
)	O
with	O
oligo	B-IUPAC
(	I-IUPAC
gamma	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamate	I-IUPAC
)	I-IUPAC
benzyl	I-IUPAC
esters	I-IUPAC
,	O
removal	O
of	O
blocking	O
groups	O
by	O
catalytic	O
hydrogenolysis	O
,	O
and	O
introduction	O
of	O
the	O
(	B-IUPAC
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
pteridinyl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
grouping	B-MODIFIER
by	O
alkylation	O
with	O
6	B-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
pteridinediamine	I-IUPAC
hydrobromide	I-IUPAC
.	O
The	O
(	O
4R	O
,	O
5R	O
)	O
-	O
stereoisomer	O
1a	O
-	O
h	O
exhibited	O
the	O
higher	O
antitumor	O
activity	O
than	O
the	O
corresponding	O
(	O
4S	O
,	O
5S	O
)	O
-	O
stereoisomer	O
2a	O
-	O
h	O
in	O
the	O
(	B-IUPAC
1,1	I-IUPAC
-	I-IUPAC
cyclobutanedicarboxylato	I-IUPAC
)	I-IUPAC
platinum	I-IUPAC
(	I-IUPAC
II	I-IUPAC
)	I-IUPAC
complexes	B-MODIFIER
.	O
The	O
in	O
vitro	O
pharmacological	O
properties	O
and	O
conformational	O
features	O
of	O
analogs	O
of	O
the	O
delta	O
opioid	O
receptor	O
selective	O
tetrapeptide	O
Tyr	O
-	O
c	O
[	O
D	O
-	O
Cys	O
-	O
Phe	O
-	O
D	O
-	O
Pen	O
]	O
OH	O
(	O
JOM	O
-	O
13	O
)	O
in	O
which	O
the	O
Phe3	O
residue	O
was	O
replaced	O
by	O
each	O
of	O
the	O
four	O
stereoisomers	O
of	O
beta	B-IUPAC
-	I-IUPAC
methylphenylalanine	I-IUPAC
(	O
beta	O
-	O
MePhe	O
)	O
were	O
investigated	O
.	O
In	O
vivo	O
noninvasive	O
optical	O
imaging	O
and	O
biodistribution	O
data	O
showed	O
that	O
the	O
compounds	O
were	O
retained	O
in	O
A549	O
tumor	O
tissue	O
.	O
Compound	O
1	O
and	O
its	O
polyglutamylated	O
homologues	O
inhibited	O
glycinamide	O
ribonucleotide	O
transformylase	O
(	O
GAR	O
-	O
TFase	O
)	O
and	O
aminoimidazole	O
ribonucleotide	O
transformylase	O
(	O
AICAR	O
-	O
TFase	O
)	O
,	O
the	O
folate	O
-	O
dependent	O
enzymes	O
in	O
de	O
novo	O
purine	O
biosynthesis	O
;	O
and	O
1	O
was	O
an	O
effective	O
substrate	O
for	O
mammalian	O
folyl	O
-	O
polyglutamate	O
synthetase	O
.	O
In	O
an	O
attempt	O
to	O
determine	O
some	O
of	O
the	O
structural	O
features	O
in	O
position	O
1	O
that	O
account	O
for	O
antivasopressor	O
activity	O
,	O
eight	O
new	O
1	O
-	O
(	O
beta	O
,	O
beta	O
-	O
dialkyl	O
-	O
substituted	O
)	O
analogues	O
of	O
1	B-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
mercaptopropanoic	I-IUPAC
acid	I-IUPAC
)	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
arginine	I-IUPAC
-	I-IUPAC
vasopressin	I-IUPAC
and	O
1	B-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
mercaptopropanoic	I-IUPAC
acid	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
methyltyrosine	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
arginine	I-IUPAC
-	I-IUPAC
vasopressin	I-IUPAC
have	O
been	O
designed	O
and	O
synthesized	O
.	O
A	O
series	O
of	O
new	O
N	B-IUPAC
-	I-IUPAC
(	I-IUPAC
pyridin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
alkylamides	I-IUPAC
44-84	O
has	O
been	O
prepared	O
in	O
the	O
search	O
of	O
novel	O
antiallergic	O
compounds	O
.	O
Two	O
simple	O
9,10	B-IUPAC
-	I-IUPAC
dihydrophenanthrenes	I-IUPAC
,	O
2,7	B-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
-	I-IUPAC
3,8	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
9,10	I-IUPAC
-	I-IUPAC
dihydrophenanthrene	I-IUPAC
(	O
2h	O
,	O
desvinyljuncusol	O
)	O
and	O
2	B-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
9,10	I-IUPAC
-	I-IUPAC
dihydrophenanthrene	I-IUPAC
(	O
3h	O
)	O
,	O
were	O
found	O
to	O
possess	O
in	O
vitro	O
antimicrobial	O
activity	O
comparable	O
with	O
that	O
of	O
the	O
natural	O
product	O
.	O
Substitution	O
with	O
ethoxymethyl	B-IUPAC
and	O
(	B-IUPAC
benzyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
groups	B-MODIFIER
further	O
potentiated	O
the	O
activity	O
[	O
EC50	O
:	O
1	B-IUPAC
-	I-IUPAC
(	I-IUPAC
ethoxy	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylthio	I-IUPAC
)	I-IUPAC
thymine	I-IUPAC
(	O
27	O
)	O
,	O
0.33	O
microM	O
;	O
1	B-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
benzyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylthio	I-IUPAC
)	I-IUPAC
thymine	I-IUPAC
(	O
31	O
)	O
,	O
0.088	O
microM	O
]	O
.	O
The	O
compounds	O
were	O
evaluated	O
as	O
inhibitors	O
of	O
DHFR	O
from	O
human	O
,	O
Pneumocystis	O
carinii	O
,	O
T	O
.	O
Out	O
of	O
the	O
33	O
novel	O
analogues	O
tested	O
for	O
the	O
duration	O
of	O
action	O
in	O
this	O
series	O
,	O
two	O
analogues	O
(	O
[	B-IUPAC
N	I-IUPAC
(	I-IUPAC
epsilon	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cyclohexyl	I-IUPAC
-	I-IUPAC
Lys	I-IUPAC
(	I-IUPAC
8	I-IUPAC
)	I-IUPAC
]	I-IUPAC
degarelix	I-IUPAC
,	O
IC	O
(	O
50	O
)	O
=	O
1.50	O
nM	O
)	O
(	O
23	O
)	O
and	O
(	O
[	B-IUPAC
N	I-IUPAC
(	I-IUPAC
beta	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
IbetaAla	I-IUPAC
)	I-IUPAC
Dap	I-IUPAC
(	I-IUPAC
8	I-IUPAC
)	I-IUPAC
]	I-IUPAC
degarelix	I-IUPAC
,	O
IC	O
(	O
50	O
)	O
=	O
1.98	O
nM	O
)	O
(	O
26	O
)	O
had	O
antagonist	O
potencies	O
and	O
duration	O
of	O
action	O
similar	O
to	O
that	O
of	O
azaline	O
B	O
{	O
inhibited	O
LH	O
(	O
&	O
gt	O
;	O
80%	O
)	O
release	O
for	O
&	O
gt	O
;	O
72	O
h	O
after	O
sc	O
injection	O
to	O
castrated	O
male	O
rats	O
at	O
a	O
standard	O
dose	O
of	O
50	O
mug	O
/	O
rat	O
in	O
5%	O
mannitol	O
}	O
.	O
The	O
results	O
establish	O
that	O
alpha	B-IUPAC
-	I-IUPAC
naphthoflavone	I-IUPAC
is	O
the	O
most	O
effective	O
in	O
vitro	O
inhibitor	O
.	O
These	O
four	O
compounds	O
together	O
with	O
the	O
2	B-IUPAC
-	I-IUPAC
desamino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
analogue	B-MODIFIER
were	O
tested	O
for	O
their	O
activity	O
against	O
L1210	O
thymidylate	O
synthase	O
(	O
TS	O
)	O
.	O
The	O
nature	O
of	O
the	O
substituents	O
on	O
the	O
mesoionic	O
ring	O
did	O
not	O
appear	O
to	O
have	O
marked	O
effects	O
on	O
potency	O
unlike	O
the	O
marked	O
effect	O
of	O
the	O
nature	O
of	O
1,3	O
-	O
substituents	O
on	O
activity	O
of	O
nonmesoionic	O
xanthines	O
.	O
In	O
order	O
to	O
develop	O
tracers	O
with	O
higher	O
specific	O
activity	O
to	O
supplant	O
the	O
currently	O
used	O
[	O
3H	O
]	O
-	O
8	O
-	O
OH	O
-	O
DPAT	O
[	O
8	B-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylamino	I-IUPAC
)	I-IUPAC
tetralin	I-IUPAC
]	O
for	O
in	O
vitro	O
and	O
in	O
vivo	O
evaluation	O
of	O
5	O
-	O
HT1A	O
receptors	O
,	O
a	O
new	O
radioiodinated	O
ligand	O
was	O
prepared	O
.	O
The	O
compound	O
3h	O
,	O
which	O
has	O
a	O
3	B-IUPAC
-	I-IUPAC
dimethylaminopropyl	I-IUPAC
substituent	B-MODIFIER
on	O
the	O
quinolone	O
nitrogen	O
and	O
a	O
methoxycarbonyl	B-IUPAC
substituent	B-MODIFIER
at	O
position	O
9	O
,	O
had	O
marked	O
antitumor	O
activity	O
.	O
All	O
analogues	O
were	O
found	O
to	O
be	O
antagonists	O
unable	O
to	O
activate	O
the	O
adenylate	O
cyclase	O
system	O
even	O
at	O
concentrations	O
as	O
high	O
as	O
10	O
(	O
-	O
5	O
)	O
M	O
except	O
for	O
analogues	O
6	O
and	O
8	O
,	O
which	O
were	O
found	O
to	O
be	O
weak	O
partial	O
agonists	O
/	O
partial	O
antagonists	O
with	O
maximum	O
stimulation	O
between	O
6-12%	O
.	O
The	O
modification	O
of	O
the	O
substituents	O
on	O
the	O
indoline	O
ring	O
of	O
4b	O
has	O
led	O
to	O
the	O
separation	O
of	O
these	O
activities	O
.	O
The	O
most	O
active	O
compounds	O
are	O
the	O
alkyl	O
derivatives	O
of	O
the	O
2	B-IUPAC
-	I-IUPAC
mesitylamino	I-IUPAC
/	O
2	B-IUPAC
-	I-IUPAC
mesitylimino	I-IUPAC
tautomeric	B-MODIFIER
forms	I-MODIFIER
.	O
With	O
use	O
of	O
the	O
correlation	O
as	O
a	O
guide	O
,	O
one	O
additional	O
5	B-IUPAC
-	I-IUPAC
phenylpyrazolo	I-IUPAC
[	I-IUPAC
4,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
containing	O
a	O
4	B-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
sulfonyl	I-IUPAC
substituent	B-MODIFIER
to	O
improve	O
aqueous	O
solubility	O
was	O
prepared	O
.	O
The	O
four	O
optically	O
pure	O
compounds	O
were	O
tested	O
in	O
vitro	O
on	O
guinea	O
pig	O
and	O
their	O
muscarinic	O
potency	O
was	O
evaluated	O
at	O
M3	O
(	O
ileum	O
and	O
bladder	O
)	O
and	O
M2	O
(	O
heart	O
)	O
muscarinic	O
receptor	O
subtypes	O
.	O
Two	O
members	O
of	O
this	O
series	O
,	O
[	B-IUPAC
R	I-IUPAC
-	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5,5	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
pyridinyl	I-IUPAC
)	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
pentadienamide	I-IUPAC
(	O
31	O
)	O
and	O
[	B-IUPAC
R	I-IUPAC
-	I-IUPAC
(	I-IUPAC
E	I-IUPAC
,	I-IUPAC
E	I-IUPAC
)	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methoxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
pyridinyl	I-IUPAC
)	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
decadienamide	I-IUPAC
(	O
58	O
)	O
,	O
were	O
selected	O
for	O
further	O
pharmacological	O
evaluation	O
.	O
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
Hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
benzimidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
(	O
45	O
,	O
K	O
(	O
i	O
)	O
=	O
6	O
nM	O
)	O
potentiates	O
the	O
cytotoxicity	O
of	O
both	O
temozolomide	O
and	O
topotecan	O
against	O
A2780	O
cells	O
in	O
vitro	O
(	O
by	O
2.8	O
-	O
and	O
2.9	O
-	O
fold	O
,	O
respectively	O
)	O
.	O
These	O
compounds	O
were	O
tested	O
for	O
their	O
ability	O
to	O
displace	O
[	O
3H	O
]	O
BTCP	O
and	O
[	O
3H	O
]	O
cocaine	O
and	O
to	O
inhibit	O
[	O
3H	O
]	O
DA	O
uptake	O
in	O
rat	O
striatal	O
homogenates	O
.	O
In	O
the	O
primary	O
anthelmintic	O
screen	O
,	O
3	B-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isothiocyanatophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
oxadiazole	I-IUPAC
(	O
39	O
)	O
showed	O
100%	O
nematocidal	O
activity	O
and	O
3	B-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isothiocyanatophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
oxadiazole	I-IUPAC
(	O
63	O
)	O
,	O
3	B-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isothiocyanatophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
oxadiazole	I-IUPAC
(	O
64	O
)	O
,	O
and	O
3	B-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
isothiocyanatophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
oxadiazole	I-IUPAC
(	O
66	O
)	O
showed	O
100%	O
taeniacidal	O
activity	O
when	O
administered	O
orally	O
to	O
mice	O
.	O
The	O
compounds	O
,	O
1	B-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dihydrobenzofuran	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminopropane	I-IUPAC
(	O
6a	O
)	O
and	O
its	O
7	O
-	O
brominated	O
analogue	O
6b	O
,	O
possessed	O
activity	O
comparable	O
to	O
their	O
conformationally	O
flexible	O
counterparts	O
1	B-IUPAC
-	I-IUPAC
(	I-IUPAC
2,5	I-IUPAC
-	I-IUPAC
dimethoxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminopropane	I-IUPAC
(	O
3	O
)	O
and	O
its	O
4	O
-	O
bromo	O
derivative	O
DOB	O
(	O
5	O
)	O
,	O
respectively	O
.	O
In	O
direct	O
contrast	O
,	O
nearly	O
all	O
of	O
the	O
thioamide	B-IUPAC
derivates	B-MODIFIER
6a	O
-	O
1	O
,	O
including	O
the	O
aglycone	O
of	O
thiosangivamycin	O
(	O
6m	O
)	O
,	O
were	O
good	O
inhibitors	O
of	O
HCMV	O
and	O
HSV	O
-	O
1	O
.	O
[	O
Carbonyl	O
-	O
11C	O
]	O
4a	O
cleared	O
the	O
brain	O
with	O
a	O
biological	O
half	O
-	O
life	O
averaging	O
41	O
min	O
.	O
With	O
FdUrd	O
-	O
resistant	O
L5178Y	O
cells	O
,	O
5	B-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
N	I-IUPAC
(	I-IUPAC
4	I-IUPAC
)	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxycytidine	I-IUPAC
(	O
5e	O
)	O
caused	O
almost	O
3	O
-	O
fold	O
stronger	O
growth	O
inhibition	O
than	O
FdUrd	O
;	O
5e	O
was	O
only	O
some	O
3	O
-	O
fold	O
weaker	O
growth	O
inhibitor	O
of	O
the	O
resistant	O
cells	O
than	O
of	O
the	O
parental	O
cells	O
.	O
The	O
best	O
substrates	O
of	O
the	O
studied	O
series	O
for	O
NOS	O
I	O
and	O
NOS	O
III	O
were	O
N	B-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
para	I-PARTIUPAC
-	I-PARTIUPAC
hydroxyphenyl	I-PARTIUPAC
)	I-PARTIUPAC
and	O
N	B-IUPAC
-	I-IUPAC
(	I-IUPAC
meta	I-IUPAC
-	I-IUPAC
aminophenyl	I-IUPAC
)	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
hydroxyguanidine	I-IUPAC
,	O
respectively	O
.	O
In	O
general	O
,	O
moderate	O
affinities	O
for	O
the	O
polyamine	O
transporter	O
were	O
observed	O
for	O
the	O
N	B-IUPAC
-	I-IUPAC
arylmethyl	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
triamine	I-IUPAC
series	B-MODIFIER
with	O
their	O
L1210	O
K	O
(	O
i	O
)	O
values	O
all	O
near	O
3	O
microM	O
.	O
In	O
the	O
case	O
of	O
5	B-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
cytosine	B-IUPAC
analogues	B-MODIFIER
,	O
the	O
antiviral	O
potency	O
was	O
found	O
to	O
be	O
in	O
the	O
following	O
decreasing	O
order	O
:	O
cytosine	O
(	O
beta	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
5	B-IUPAC
-	I-IUPAC
iodocytosine	I-IUPAC
(	O
beta	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
5	B-IUPAC
-	I-IUPAC
fluorocytosine	I-IUPAC
(	O
alpha	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
5	B-IUPAC
-	I-IUPAC
methylcytosine	I-IUPAC
(	O
alpha	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
5	B-IUPAC
-	I-IUPAC
methylcytosine	I-IUPAC
(	O
beta	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
5	B-IUPAC
-	I-IUPAC
bromocytosine	I-IUPAC
(	O
beta	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
5	B-IUPAC
-	I-IUPAC
chlorocytosine	I-IUPAC
(	O
beta	O
-	O
isomer	O
)	O
.	O
Synthesis	O
of	O
the	O
desired	O
ethyl	B-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyindol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
acetates	I-IUPAC
1-4	O
was	O
achieved	O
by	O
indolization	O
under	O
Fischer	O
conditions	O
;	O
Japp	O
-	O
Klingemann	O
method	O
followed	O
by	O
2	O
-	O
decarboxylation	O
afforded	O
the	O
ethyl	B-IUPAC
(	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
alkanoates	I-IUPAC
17-25	O
.	O
The	O
(	O
N	O
)	O
isomer	O
was	O
hardly	O
hydrolyzed	O
by	O
NTPDase	O
2	O
,	O
while	O
the	O
(	O
S	O
)	O
isomer	O
was	O
hydrolyzed	O
at	O
one	O
-	O
third	O
of	O
the	O
rate	O
of	O
ATP	O
hydrolysis	O
.	O
The	O
high	O
-	O
potency	O
phenolic	O
antagonist	O
21	O
and	O
its	O
low	O
-	O
potency	O
O	O
-	O
methylated	O
analogue	O
18	O
are	O
both	O
potent	O
anticonvulsants	O
in	O
a	O
mouse	O
maximal	O
electroshock	O
-	O
induced	O
seizure	O
(	O
MES	O
)	O
study	O
(	O
ED	O
(	O
50	O
)	O
(	O
iv	O
)	O
=	O
0.23	O
and	O
0.56	O
mg	O
/	O
kg	O
,	O
respectively	O
)	O
.	O
The	O
structure	O
-	O
activity	O
relationship	O
(	O
SAR	O
)	O
associated	O
with	O
position	O
1	O
and	O
3	O
substituents	O
in	O
beta	O
-	O
carbolines	O
has	O
been	O
discussed	O
.	O
The	O
solubility	O
of	O
platinum	O
complexes	O
was	O
related	O
to	O
the	O
nature	O
of	O
leaving	O
ligands	O
and	O
2	O
-	O
substituents	O
in	O
the	O
4,5	B-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
aminomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dioxolane	I-IUPAC
carrier	O
ligands	O
.	O
Moderate	O
activity	O
was	O
observed	O
against	O
P388	O
leukemia	O
in	O
vivo	O
.	O
Comparison	O
of	O
the	O
binding	O
data	O
of	O
different	O
N	O
-	O
substituted	O
homologues	O
of	O
1	O
with	O
those	O
of	O
the	O
1	B-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dichlorophenyl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
alkylpiperazines	I-IUPAC
suggests	O
that	O
the	O
two	O
nitrogen	O
atoms	O
of	O
1	O
are	O
working	O
in	O
opposition	O
to	O
one	O
another	O
in	O
terms	O
of	O
their	O
sensitivity	O
to	O
steric	O
bulk	O
.	O
Selected	O
compounds	O
were	O
also	O
tested	O
for	O
their	O
affinity	O
to	O
the	O
D1	O
(	O
rat	O
striatum	O
)	O
,	O
D2	O
(	O
rat	O
striatum	O
)	O
,	O
D2A	O
(	O
human	O
cloned	O
)	O
,	O
and	O
5	O
-	O
HT2A	O
(	O
rat	O
cortex	O
)	O
receptors	O
.	O
This	O
amide	O
was	O
406	O
-	O
fold	O
more	O
potent	O
than	O
astemizole	O
in	O
the	O
ovalbumin	O
-	O
induced	O
histamine	O
release	O
assay	O
,	O
using	O
guinea	O
pig	O
peritoneal	O
mast	O
cells	O
,	O
with	O
an	O
IC50	O
=	O
0.016	O
microM	O
.	O
Substitution	O
at	O
the	O
1	O
-	O
position	O
was	O
necessary	O
for	O
high	O
affinity	O
at	O
adenosine	O
receptors	O
.	O
These	O
guanidines	O
are	O
radiotracer	O
analogues	O
of	O
guanethidine	O
,	O
an	O
antihypertensive	O
agent	O
thought	O
to	O
mediate	O
neuron	O
blockade	O
by	O
uptake	O
into	O
adrenergic	O
nerves	O
.	O
The	O
data	O
revealed	O
that	O
when	O
neutral	O
molecules	O
(	O
cargo	O
fragments	O
)	O
were	O
fixed	O
to	O
the	O
polyamine	O
vector	O
,	O
the	O
conjugates	O
competed	O
well	O
with	O
spermidine	O
for	O
transport	O
and	O
were	O
accumulated	O
intracellularly	O
to	O
millimolar	O
levels	O
.	O
Degarelix	O
(	O
FE200486	O
,	O
Ac	O
-	O
d	O
-	O
2Nal	O
(	O
1	O
)	O
-	O
d	O
-	O
4Cpa	O
(	O
2	O
)	O
-	O
d	O
-	O
3Pal	O
(	O
3	O
)	O
-	O
Ser	O
(	O
4	O
)	O
-	O
4Aph	O
(	O
l	O
-	O
Hor	O
)	O
(	O
5	O
)	O
-	O
d	O
-	O
4Aph	O
(	O
Cbm	O
)	O
(	O
6	O
)	O
-	O
Leu	O
(	O
7	O
)	O
-	O
ILys	O
(	O
8	O
)	O
-	O
Pro	O
(	O
9	O
)	O
-	O
d	O
-	O
Ala	O
(	O
10	O
)	O
-	O
NH	O
(	O
2	O
)	O
)	O
is	O
a	O
potent	O
and	O
very	O
long	O
acting	O
antagonist	O
of	O
gonadotropin	O
-	O
releasing	O
hormone	O
(	O
GnRH	O
)	O
after	O
subcutaneous	O
administration	O
in	O
mammals	O
including	O
humans	O
.	O
For	O
comparison	O
reasons	O
,	O
the	O
cytotoxicity	O
of	O
the	O
complexes	O
alpha	O
-	O
[	O
Ru	O
(	O
azpy	O
)	O
(	O
2	O
)	O
Cl	O
(	O
2	O
)	O
]	O
,	O
alpha	O
-	O
[	O
Ru	O
(	O
azpy	O
)	O
(	O
2	O
)	O
(	O
NO	O
(	O
3	O
)	O
)	O
(	O
2	O
)	O
]	O
,	O
beta	O
-	O
[	O
Ru	O
(	O
azpy	O
)	O
(	O
2	O
)	O
Cl	O
(	O
2	O
)	O
]	O
(	O
beta	O
indicating	O
the	O
coordinating	O
pairs	O
Cl	O
,	O
N	O
(	O
py	O
)	O
,	O
and	O
N	O
(	O
azo	O
)	O
as	O
cis	O
,	O
cis	O
,	O
cis	O
,	O
respectively	O
)	O
,	O
and	O
beta	O
-	O
[	O
Ru	O
(	O
azpy	O
)	O
(	O
2	O
)	O
(	O
NO	O
(	O
3	O
)	O
)	O
(	O
2	O
)	O
]	O
have	O
been	O
determined	O
in	O
this	O
cell	O
line	O
.	O
All	O
target	O
compounds	O
were	O
evaluated	O
for	O
their	O
inhibitory	O
effects	O
on	O
apomorphine	O
-	O
induced	O
stereotyped	O
behavior	O
in	O
rats	O
,	O
and	O
a	O
good	O
correlation	O
between	O
structure	O
and	O
activity	O
was	O
found	O
throughout	O
the	O
series	O
.	O
The	O
Kd	O
for	O
[	O
64Cu	O
]	O
CPTA	O
-	O
D	O
-	O
Phe1	O
-	O
octreotide	O
was	O
78.5	O
pM	O
.	O
A	O
number	O
of	O
3,4	B-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
pyrazolo	B-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
ribonucleosides	B-MODIFIER
were	O
synthesized	O
and	O
tested	O
for	O
their	O
biological	O
activity	O
.	O
We	O
initially	O
investigated	O
the	O
stability	O
of	O
1	O
in	O
guinea	O
pig	O
plasma	O
and	O
liver	O
homogenate	O
to	O
elucidate	O
the	O
most	O
labile	O
part	O
in	O
the	O
structure	O
.	O
The	O
cytotoxic	O
activities	O
of	O
the	O
derived	O
compounds	O
against	O
the	O
human	O
tumor	O
cell	O
lines	O
were	O
equal	O
to	O
or	O
greater	O
than	O
that	O
of	O
the	O
lead	O
compound	O
.	O
Synthetic	O
procedures	O
for	O
the	O
preparation	O
of	O
various	O
3	B-MODIFIER
-	I-MODIFIER
unsubstituted	I-MODIFIER
xanthines	B-IUPAC
,	O
including	O
paraxanthine	O
analogs	O
(	O
1,7	B-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
xanthines	B-IUPAC
)	O
and	O
1,8	B-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
xanthines	B-IUPAC
,	O
were	O
developed	O
.	O
Also	O
examined	O
were	O
analogues	O
in	O
which	O
tyrosine	O
was	O
replaced	O
with	O
either	O
trans	B-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
proline	I-IUPAC
(	O
t	O
-	O
Hpp	O
)	O
or	O
cis	B-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
proline	I-IUPAC
(	O
c	O
-	O
Hpp	O
)	O
,	O
residues	O
in	O
which	O
rotations	O
about	O
C	O
alpha	O
-	O
C	O
beta	O
,	O
but	O
not	O
C	O
beta	O
-	O
C	O
gamma	O
,	O
are	O
restricted	O
.	O
The	O
affinity	O
and	O
selectivity	O
of	O
these	O
compounds	O
for	O
D	O
-	O
1	O
and	O
D	O
-	O
2	O
subtypes	O
was	O
determined	O
in	O
radioligand	O
competition	O
assays	O
for	O
the	O
DA	O
receptors	O
of	O
rat	O
striatum	O
membranes	O
using	O
[	O
3H	O
]	O
SCH	O
23390	O
(	O
D	O
-	O
1	O
selective	O
)	O
and	O
[	O
3H	O
]	O
spiperone	O
(	O
D	O
-	O
2	O
selective	O
)	O
as	O
radioligands	O
.	O
All	O
compounds	O
were	O
tested	O
for	O
A1	O
adenosine	O
receptor	O
affinity	O
by	O
using	O
a	O
(	B-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
N6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylisopropyl	I-IUPAC
)	I-IUPAC
adenosine	I-IUPAC
binding	O
assay	O
.	O
However	O
,	O
the	O
potency	O
of	O
all	O
of	O
these	O
latter	O
derivatives	O
was	O
at	O
least	O
1	O
order	O
of	O
magnitude	O
less	O
than	O
[	O
dPen1	O
,	O
cyclo	O
(	O
Glu4	O
,	O
Lys8	O
)	O
]	O
oxytocin	O
.	O
4	B-IUPAC
-	I-IUPAC
Butylhomoibotenic	I-IUPAC
acid	I-IUPAC
(	O
4c	O
)	O
and	O
4	B-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethyl	I-IUPAC
)	I-IUPAC
homoibotenic	I-IUPAC
acid	I-IUPAC
(	O
4e	O
)	O
were	O
equipotent	O
as	O
inhibitors	O
of	O
[	O
3H	O
]	O
AMPA	O
binding	O
(	O
IC50	O
=	O
2	O
microM	O
)	O
and	O
showed	O
similar	O
excitatory	O
activity	O
in	O
the	O
rat	O
cortical	O
slice	O
preparation	O
.	O
Pirenzepine	O
displayed	O
the	O
highest	O
affinity	O
for	O
hippocampal	O
,	O
striatal	O
,	O
and	O
amygdaloid	O
muscarinic	O
receptors	O
(	O
IC50	O
values	O
less	O
than	O
0.4	O
microM	O
)	O
,	O
with	O
a	O
slightly	O
lower	O
affinity	O
for	O
cortical	O
receptors	O
(	O
IC50	O
values	O
between	O
0.4	O
and	O
0.8	O
microM	O
)	O
.	O
A	O
broad	O
structure	O
-	O
activity	O
program	O
was	O
undertaken	O
in	O
search	O
of	O
effective	O
surrogates	O
for	O
the	O
key	O
benzothiazole	O
side	O
chain	O
of	O
the	O
potent	O
aldose	O
reductase	O
inhibitor	O
,	O
zopolrestat	O
(	O
1	O
)	O
.	O
It	O
was	O
hypothesized	O
that	O
the	O
reduced	O
flexibility	O
of	O
indoles	O
4-8	O
would	O
both	O
facilitate	O
the	O
mapping	O
of	O
the	O
BzR	O
binding	O
cleft	O
and	O
increase	O
the	O
chances	O
of	O
conferring	O
selectivity	O
for	O
the	O
considered	O
receptor	O
subtypes	O
.	O
DFO	O
-	O
HOPO	O
and	O
3,4,3	O
-	O
LIHOPO	O
and	O
its	O
Zn	O
(	O
II	O
)	O
and	O
Fe	O
(	O
III	O
)	O
complexes	O
promoted	O
significantly	O
more	O
Pu	O
excretion	O
than	O
CaNa3	O
-	O
DTPA	O
(	O
61%	O
of	O
injected	O
Pu	O
)	O
.	O
We	O
have	O
previously	O
shown	O
that	O
(	B-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolyl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
[	O
(	O
S	O
)	O
-	O
APPA	O
,	O
2	O
]	O
is	O
a	O
weak	O
agonist	O
at	O
(	B-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolyl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
AMPA	O
)	O
receptors	O
,	O
specifically	O
activated	O
by	O
(	O
S	O
)	O
-	O
AMPA	O
(	O
1	O
)	O
,	O
whereas	O
(	B-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolyl	I-IUPAC
]	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
[	O
(	O
S	O
)	O
-	O
2	O
-	O
Py	O
-	O
AMPA	O
,	O
5	O
]	O
and	O
(	B-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thiazolyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolyl	I-IUPAC
]	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
4	O
)	O
are	O
potent	O
AMPA	O
agonists	O
.	O
The	O
novel	O
acidic	O
amino	O
acids	O
6a	O
-	O
c	O
,	O
7	O
,	O
and	O
8	O
have	O
been	O
synthesized	O
via	O
1,3	O
-	O
dipolar	O
cycloadditions	O
,	O
using	O
nitrile	O
oxides	O
and	O
alkynes	O
.	O
Two	O
major	O
diastereomers	O
of	O
[	O
99mTc	O
]	O
TRODAT	O
-	O
1	O
(	O
2	O
)	O
,	O
designated	O
as	O
peak	O
A	O
(	O
2A	O
)	O
and	O
peak	O
B	O
(	O
2B	O
)	O
,	O
were	O
separated	O
by	O
HPLC	O
.	O
1	B-IUPAC
-	I-IUPAC
Hydroxy	I-IUPAC
-	I-IUPAC
1,2,3	I-IUPAC
-	I-IUPAC
triazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
analogues	B-MODIFIER
of	O
AMPA	O
,	O
compounds	O
8a	O
,	O
b	O
,	O
showed	O
high	O
affinity	O
for	O
[	O
3H	O
]	O
AMPA	O
receptor	O
binding	O
sites	O
(	O
IC	O
(	O
50	O
)	O
=	O
0.15	O
+	O
/	O
-	O
0.03	O
microM	O
and	O
IC	O
(	O
50	O
)	O
=	O
0.13	O
+	O
/	O
-	O
0.02	O
microM	O
,	O
respectively	O
)	O
.	O
The	O
agonists	O
are	O
characterized	O
in	O
terms	O
of	O
their	O
in	O
vitro	O
profiles	O
,	O
both	O
binding	O
and	O
functional	O
,	O
and	O
in	O
vivo	O
activity	O
in	O
relevant	O
animal	O
models	O
.	O
Preliminary	O
stroke	O
results	O
from	O
1	B-PARTIUPAC
-	I-PARTIUPAC
and	O
2	B-IUPAC
-	I-IUPAC
aza	I-IUPAC
-	I-IUPAC
5	I-IUPAC
[	I-IUPAC
H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
phenanthridin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
one	I-IUPAC
prompted	O
structure	O
-	O
activity	O
relationships	O
to	O
be	O
established	O
for	O
several	O
2	B-MODIFIER
-	I-MODIFIER
and	O
3	B-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
1	B-IUPAC
-	I-IUPAC
aza	I-IUPAC
-	I-IUPAC
5	I-IUPAC
[	I-IUPAC
H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
phenanthridin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
.	O
The	O
[	B-IUPAC
1,2,4	I-IUPAC
]	I-IUPAC
triazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
triazine	I-IUPAC
derivative	B-MODIFIER
3	O
,	O
more	O
commonly	O
known	O
in	O
the	O
field	O
of	O
adenosine	O
research	O
as	O
ZM	O
-	O
241385	O
,	O
has	O
previously	O
been	O
demonstrated	O
to	O
be	O
a	O
potent	O
and	O
selective	O
adenosine	O
A2a	O
receptor	O
antagonist	O
,	O
although	O
with	O
limited	O
oral	O
bioavailability	O
.	O
7	B-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
3	B-IUPAC
-	I-IUPAC
(	I-IUPAC
2,6	I-IUPAC
-	I-IUPAC
dichlorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,6	I-IUPAC
-	I-IUPAC
naphthyridin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
are	O
potent	O
inhibitors	O
of	O
protein	O
tyrosine	O
kinases	O
,	O
with	O
some	O
selectivity	O
for	O
c	O
-	O
Src	O
.	O
The	O
determination	O
of	O
the	O
structure	O
and	O
function	O
of	O
the	O
sigma	O
receptor	O
subtypes	O
and	O
their	O
physiological	O
role	O
(	O
s	O
)	O
has	O
been	O
impeded	O
by	O
the	O
unavailability	O
of	O
selective	O
ligands	O
.	O
The	O
carbonyl	B-IUPAC
group	B-MODIFIER
at	O
position	O
4	O
of	O
the	O
4	B-IUPAC
-	I-IUPAC
chromanone	I-IUPAC
was	O
essential	O
for	O
potent	O
ACAT	O
inhibitory	O
activity	O
.	O
A	O
series	O
of	O
erythro	B-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
nonyl	I-IUPAC
)	I-IUPAC
azole	I-IUPAC
derivatives	B-MODIFIER
have	O
been	O
synthesized	O
and	O
evaluated	O
for	O
adenosine	O
deaminase	O
(	O
ADA	O
)	O
inhibitory	O
activity	O
,	O
in	O
order	O
to	O
introduce	O
simplifications	O
in	O
the	O
ADA	O
inhibitor	O
erythro	B-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
nonyl	I-IUPAC
)	I-IUPAC
adenine	I-IUPAC
(	O
EHNA	O
,	O
1a	O
)	O
.	O
Nitration	O
of	O
4	O
,	O
followed	O
by	O
oxidation	O
with	O
selenium	O
dioxide	O
,	O
produced	O
aldehyde	O
18	O
,	O
which	O
was	O
then	O
converted	O
to	O
the	O
cyclic	O
ethylene	O
acetal	O
19	O
.	O
The	O
absolute	O
configurations	O
of	O
the	O
latter	O
were	O
established	O
by	O
conversion	O
of	O
1L	B-IUPAC
-	I-IUPAC
2,5,6	I-IUPAC
-	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
methoxybenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
myo	I-IUPAC
-	I-IUPAC
inositol	I-IUPAC
to	O
the	O
known	O
1L	B-IUPAC
-	I-IUPAC
1,2,4,5,6	I-IUPAC
-	I-IUPAC
penta	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
myo	I-IUPAC
-	I-IUPAC
inositol	I-IUPAC
.	O
carinii	O
DHFR	O
was	O
20	O
-	O
fold	O
greater	O
than	O
that	O
of	O
PTX	O
(	O
IC	O
(	O
50	O
)	O
=	O
13	O
nM	O
)	O
,	O
and	O
its	O
selectivity	O
index	O
(	O
SI	O
)	O
relative	O
to	O
rat	O
DHFR	O
was	O
85	O
,	O
whereas	O
PTX	O
was	O
nonselective	O
.	O
Hydrogenolytic	O
removal	O
of	O
the	O
carbobenzyloxy	O
groups	O
,	O
followed	O
by	O
iodoacetylation	O
of	O
the	O
omega	O
-	O
amino	O
groups	O
with	O
N	B-IUPAC
-	I-IUPAC
(	I-IUPAC
iodoacetoxy	I-IUPAC
)	I-IUPAC
succinimide	I-IUPAC
,	O
gave	O
N6	O
-	O
R	O
-	O
ATP	O
,	O
where	O
R	O
=	O
(	O
CH2	O
)	O
nNHCOCH2I	O
(	O
n	O
=	O
2	O
-	O
-	O
8	O
)	O
or	O
(	O
CH2	O
)	O
nCON	O
)	O
CH3	O
)	O
(	O
CH2	O
)	O
mN	O
(	O
CH3	O
)	O
CO	O
(	O
CH2	O
)	O
nNHCOCH2I	O
(	O
n	O
=	O
m	O
=	O
3	O
;	O
n	O
=	O
3	O
,	O
m	O
=	O
4	O
;	O
n	O
=	O
4	O
,	O
m	O
=	O
3	O
;	O
n	O
=	O
m	O
=	O
4	O
)	O
.	O
The	O
rates	O
of	O
hydrolysis	O
of	O
Northern	O
(	O
N	O
)	O
and	O
Southern	O
(	O
S	O
)	O
methanocarba	O
analogues	O
of	O
AMP	O
by	O
rat	O
5'	O
-	O
ectonucleotidase	O
were	O
negligible	O
.	O
An	O
n	B-IUPAC
-	I-IUPAC
propyl	I-IUPAC
group	B-MODIFIER
gives	O
high	O
dopaminergic	O
efficacy	O
at	O
both	O
receptor	O
sites	O
(	O
pre	O
-	O
and	O
postsynaptic	O
)	O
in	O
all	O
series	O
.	O
Binding	O
to	O
alpha	O
1	O
-	O
ARs	O
was	O
relatively	O
sensitive	O
to	O
size	O
and	O
electronic	O
features	O
of	O
the	O
arylpiperazine	B-IUPAC
portion	O
of	O
the	O
antagonists	O
and	O
permissive	O
to	O
these	O
features	O
on	O
the	O
heteroaryl	O
carboxamide	O
side	O
.	O
The	O
third	O
step	O
is	O
the	O
P	O
-	O
N	O
ring	O
opening	O
of	O
the	O
oxazaphosphorines	O
3a	O
,	O
b	O
leading	O
to	O
the	O
phosphoric	O
acid	O
monoesters	O
,	O
H	O
(	O
2	O
)	O
N	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
3	O
)	O
OP	O
(	O
O	O
)	O
(	O
OH	O
)	O
(	O
2	O
)	O
(	O
4a	O
)	O
and	O
Cl	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
2	O
)	O
HN	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
3	O
)	O
OP	O
(	O
O	O
)	O
(	O
OH	O
)	O
(	O
2	O
)	O
(	O
4b	O
-	O
1	O
)	O
,	O
respectively	O
.	O
The	O
sigma	O
receptor	O
binding	O
affinities	O
of	O
these	O
compounds	O
were	O
determined	O
using	O
[	B-IUPAC
3H	I-IUPAC
]	I-IUPAC
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pentazocine	I-IUPAC
in	O
guinea	O
pig	O
brain	O
homogenates	O
.	O
(	O
1	O
)	O
Other	O
closely	O
related	O
analogues	O
,	O
such	O
as	O
those	O
where	O
the	O
[	O
DAsp	O
(	O
1	O
)	O
(	O
betaAla	O
)	O
,	O
DOrn	O
(	O
3	O
)	O
]	O
cycle	O
of	O
21	O
was	O
changed	O
to	O
[	O
DOrn	O
(	O
1	O
)	O
(	O
betaAla	O
)	O
,	O
DAsp	O
(	O
3	O
)	O
]	O
of	O
cyclo	O
(	O
1,1	O
'	O
-	O
3	O
)	O
[	O
Ac	O
-	O
DOrn	O
(	O
1	O
)	O
(	O
betaAla	O
)	O
,	O
DCpa	O
(	O
2	O
)	O
,	O
DAsp	O
(	O
3	O
)	O
,	O
DNal	O
(	O
6	O
)	O
,	O
DAla	O
(	O
10	O
)	O
]	O
GnRH	O
(	O
22	O
,	O
K	O
(	O
i	O
)	O
=	O
2.2	O
nM	O
)	O
or	O
where	O
the	O
size	O
of	O
the	O
cycle	O
was	O
conserved	O
and	O
[	O
DAsp	O
(	O
1	O
)	O
(	O
betaAla	O
)	O
,	O
DOrn	O
(	O
3	O
)	O
]	O
was	O
replaced	O
by	O
[	O
DGlu	O
(	O
1	O
)	O
(	O
Gly	O
)	O
,	O
DOrn	O
(	O
3	O
)	O
]	O
as	O
in	O
cyclo	O
(	O
1	O
,	O
1'	O
-	O
3	O
)	O
[	O
Ac	O
-	O
DGlu	O
(	O
1	O
)	O
(	O
Gly	O
)	O
,	O
DCpa	O
(	O
2	O
)	O
,	O
DOrn	O
(	O
3	O
)	O
,	O
DNal	O
(	O
6	O
)	O
,	O
DA	O
la	O
(	O
10	O
)	O
]	O
GnRH	O
(	O
23	O
,	O
K	O
(	O
i	O
)	O
=	O
4.2	O
nM	O
)	O
,	O
were	O
approximately	O
100	O
and	O
25	O
times	O
less	O
potent	O
in	O
vivo	O
,	O
respectively	O
.	O
One	O
of	O
these	O
,	O
9	B-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
7,8,9,10	I-IUPAC
-	I-IUPAC
tetrahydropyrido	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
e	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,2,4	I-IUPAC
]	I-IUPAC
triazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
5	I-IUPAC
(	I-IUPAC
6H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
,	O
showed	O
good	O
activity	O
in	O
rats	O
as	O
a	O
potential	O
anxiolytic	O
agent	O
without	O
sedative	O
liability	O
.	O
Deamination	O
of	O
12	O
with	O
nitrous	O
acid	O
produced	O
3	O
,	O
thereby	O
confirming	O
that	O
alkylation	O
of	O
5	B-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
[	I-IUPAC
(	I-IUPAC
trimethylsilyl	I-IUPAC
)	I-IUPAC
oxy	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
had	O
occurred	O
at	O
N1	O
.	O
The	O
latter	O
reaction	O
with	O
6	B-PARTIUPAC
-	I-PARTIUPAC
(	O
substituted	B-MODIFIER
amino	B-IUPAC
)	O
-	B-PARTIUPAC
4,5	I-PARTIUPAC
-	I-PARTIUPAC
diaminopyridines	I-PARTIUPAC
gave	O
imidazo	B-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
ring	B-MODIFIER
analogues	I-MODIFIER
of	O
1	O
.	O
In	O
these	O
compounds	O
,	O
the	O
planes	O
of	O
the	O
phenyl	O
and	O
piperidyl	O
moieties	O
of	O
the	O
parent	O
ligand	O
1	O
are	O
held	O
at	O
right	O
angles	O
by	O
vinyl	O
,	O
ethylene	O
,	O
and	O
propylene	O
bridges	O
to	O
form	O
N	B-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
derivatives	B-MODIFIER
of	O
spiro	B-IUPAC
[	I-IUPAC
indene	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
'	I-IUPAC
-	I-IUPAC
piperidine	I-IUPAC
]	I-IUPAC
,	O
2,3	B-IUPAC
-	I-IUPAC
dihydrospiro	I-IUPAC
[	I-IUPAC
indene	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
'	I-IUPAC
-	I-IUPAC
piperidine	I-IUPAC
]	I-IUPAC
,	O
and	O
3,4	B-IUPAC
-	I-IUPAC
dihydrospiro	I-IUPAC
[	I-IUPAC
naphthalene	I-IUPAC
-	I-IUPAC
1	I-IUPAC
(	I-IUPAC
2H	I-IUPAC
)	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
piperidine	I-IUPAC
]	I-IUPAC
,	O
respectively	O
.	O
Inclusion	O
of	O
ClogP	O
did	O
not	O
improve	O
the	O
models	O
significantly	O
and	O
exhibited	O
comparable	O
correlation	O
coefficients	O
with	O
CoMFA	O
steric	O
and	O
electrostatic	O
models	O
.	O
The	O
ineffectiveness	O
of	O
6	B-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
alkylpyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
is	O
imputable	O
to	O
the	O
alkyl	O
chain	O
which	O
could	O
hinder	O
the	O
coordination	O
with	O
molybdenum	O
according	O
to	O
the	O
known	O
mechanism	O
for	O
the	O
binding	O
of	O
the	O
inhibitor	O
allopurinol	O
;	O
the	O
effectiveness	O
of	O
imidazole	O
derivatives	O
,	O
by	O
contrast	O
with	O
the	O
ineffectiveness	O
of	O
4,5	B-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
thioalkyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
hydroxypyrimidines	I-IUPAC
,	O
indicates	O
the	O
relative	O
importance	O
of	O
the	O
five	O
-	O
membered	O
ring	O
in	O
the	O
interaction	O
with	O
the	O
enzyme	O
.	O
Bromination	O
-	O
dehydrobromination	O
of	O
the	O
5'	B-IUPAC
-	I-IUPAC
bromohomovinyl	I-IUPAC
analogue	B-MODIFIER
11	O
and	O
deprotection	O
gave	O
(	B-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
,	I-IUPAC
6	I-IUPAC
-	I-IUPAC
dibromo	I-IUPAC
-	I-IUPAC
5,6	I-IUPAC
-	I-IUPAC
dideoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
d	I-IUPAC
-	I-IUPAC
ribo	I-IUPAC
-	I-IUPAC
hex	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
enofuranosyl	I-IUPAC
)	I-IUPAC
adenine	I-IUPAC
(	O
15	O
)	O
.	O
The	O
compounds	O
were	O
also	O
evaluated	O
against	O
TS	O
from	O
(	O
recombinant	O
)	O
human	O
and	O
L	O
.	O
The	O
three	O
most	O
potent	O
inhibitors	O
of	O
P	O
.	O
Cyclic	O
dianhydride	O
of	O
diethylenetriaminepentaacetic	O
acid	O
(	O
DTPA	O
)	O
was	O
coupled	O
to	O
a	O
portion	O
of	O
the	O
protected	O
peptide	O
-	O
resin	O
following	O
disulfide	O
bond	O
formation	O
.	O
Fluorescence	O
measurements	O
show	O
that	O
there	O
are	O
two	O
species	O
of	O
tomaymycin	O
bound	O
to	O
d	O
(	O
ATGCAT	O
)	O
2	O
,	O
which	O
are	O
tentatively	O
identified	O
as	O
the	O
11R	O
,	O
11aS	O
and	O
11S	O
,	O
11aS	O
diastereomers	O
.	O
The	O
best	O
inhibitor	O
of	O
P	O
.	O
On	O
the	O
basis	O
of	O
the	O
SAR	O
of	O
a	O
series	O
of	O
known	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
)	O
uptake	O
inhibitors	O
,	O
including	O
4	O
(	O
SKF	O
89976	O
)	O
,	O
new	O
tricyclic	O
analogues	O
have	O
been	O
prepared	O
.	O
6,7	B-IUPAC
-	I-IUPAC
Dihydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4H	I-IUPAC
,	I-IUPAC
5H	I-IUPAC
-	I-IUPAC
cyclopenta	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
]	I-IUPAC
thieno	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,3	I-IUPAC
]	I-IUPAC
oxazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
33	O
)	O
exhibited	O
a	O
K	O
(	O
i	O
)	O
value	O
of	O
630	O
nM	O
and	O
excelled	O
in	O
its	O
low	O
susceptibility	O
to	O
CEase	O
-	O
catalyzed	O
degradation	O
.	O
Selected	O
ion	O
-	O
monitoring	O
GC	O
-	O
MS	O
analysis	O
,	O
based	O
on	O
use	O
of	O
the	O
synthesized	O
mixture	O
of	O
diastereoisomers	O
of	O
1	B-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
naphthoxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propanol	I-IUPAC
(	O
2	O
)	O
as	O
a	O
standard	O
,	O
established	O
formation	O
of	O
both	O
diastereoisomers	O
of	O
2	O
as	O
metabolites	O
of	O
1	O
.	O
1,3	B-MODIFIER
-	I-MODIFIER
Disubstituted	I-MODIFIER
xanthines	B-IUPAC
generally	O
had	O
higher	O
affinity	O
than	O
1,7	B-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
xanthines	B-IUPAC
.	O
gondii	O
)	O
was	O
ca.	O
30	O
-	O
fold	O
higher	O
than	O
that	O
of	O
TMQ	O
or	O
PTX	O
.	O
This	O
study	O
should	O
be	O
applicable	O
to	O
other	O
biologically	O
active	O
peptides	O
.	O
Only	O
1%	O
of	O
298	O
enzyme	O
-	O
inhibitor	O
combinations	O
exhibited	O
ATP	O
-	O
site	O
-	O
directed	O
inactivation	O
,	O
signifying	O
that	O
few	O
suitably	O
positioned	O
and	O
sufficiently	O
reactive	O
nucleophilic	O
groups	O
were	O
present	O
near	O
the	O
enzymic	O
ATP	O
sites	O
.	O
In	O
general	O
,	O
an	O
8	B-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
or	O
8	B-IUPAC
-	I-IUPAC
methyl	I-IUPAC
substituent	B-MODIFIER
enhanced	O
inhibitory	O
activity	O
in	O
comparison	O
with	O
an	O
8	B-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
group	B-MODIFIER
.	O
The	O
17	O
-	O
O	O
-	O
THP	O
derivative	O
of	O
3	O
was	O
treated	O
with	O
LiAlH4	O
to	O
give	O
17beta	B-IUPAC
-	I-IUPAC
(	I-IUPAC
O	I-IUPAC
-	I-IUPAC
tetrahydropyranyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
9,11	I-IUPAC
-	I-IUPAC
secoestra	I-IUPAC
-	I-IUPAC
1,3,5	I-IUPAC
(	I-IUPAC
10	I-IUPAC
)	I-IUPAC
-	I-IUPAC
triene	I-IUPAC
(	O
5	O
)	O
.	O
In	O
this	O
model	O
,	O
ICI	O
204,219	O
was	O
active	O
at	O
0.4	O
mg	O
/	O
kg	O
.	O
Half	O
-	O
maximal	O
hydroosmotic	O
responses	O
(	O
ED	O
-	O
50	O
values	O
)	O
were	O
obtained	O
with	O
2.5	O
X	O
10	O
(	O
-	O
9	O
)	O
M	O
for	O
the	O
iodinated	O
analogue	O
,	O
with	O
0.9	O
X	O
10	O
(	O
-	O
10	O
)	O
M	O
for	O
the	O
photoaffinity	O
analogue	O
,	O
and	O
with	O
1.2	O
X	O
10	O
(	O
-	O
8	O
)	O
M	O
for	O
the	O
biotinyl	O
analogue	O
.	O
Structure	O
-	O
activity	O
studies	O
indicate	O
that	O
the	O
role	O
of	O
the	O
NPS	O
and	O
CmPS	O
moieties	O
could	O
be	O
related	O
to	O
the	O
adoption	O
of	O
a	O
preferential	O
active	O
conformation	O
.	O
Molecular	O
modeling	O
dynamics	O
studies	O
using	O
compounds	O
10	O
and	O
13	O
indicated	O
a	O
slight	O
binding	O
preference	O
for	O
the	O
latter	O
,	O
in	O
qualitative	O
agreement	O
with	O
the	O
IC	O
(	O
50	O
)	O
data	O
.	O
In	O
summary	O
,	O
there	O
are	O
clear	O
limits	O
to	O
the	O
size	O
of	O
N	O
(	O
1	O
)	O
-	O
substituents	O
,	O
which	O
can	O
be	O
accommodated	O
by	O
the	O
polyamine	O
transporter	O
.	O
Further	O
structural	O
manipulation	O
was	O
guided	O
by	O
molecular	O
modeling	O
through	O
comparison	O
of	O
fieldpoint	O
-	O
based	O
structures	O
of	O
candidate	O
compounds	O
with	O
a	O
selected	O
low	O
-	O
energy	O
conformation	O
of	O
the	O
representative	O
CCK	O
(	O
2	O
)	O
receptor	O
antagonist	O
5	B-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
1S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
3	I-IUPAC
,	I-IUPAC
5	I-IUPAC
-	I-IUPAC
dicarboxyphenyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylethyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
adamantylmethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
indole	I-IUPAC
(	O
JB93182	O
(	O
3	O
)	O
)	O
.	O
The	O
4,5	B-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
3H	I-IUPAC
-	I-IUPAC
naphtho	I-IUPAC
[	I-IUPAC
1,8	I-IUPAC
-	I-IUPAC
bc	I-IUPAC
]	I-IUPAC
thiophene	I-IUPAC
derivative	B-MODIFIER
(	B-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
7	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
pyrrolidinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
oxaspiro	I-IUPAC
[	I-IUPAC
4.5	I-IUPAC
]	I-IUPAC
dec	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3H	I-IUPAC
-	I-IUPAC
naphthol	I-IUPAC
[	I-IUPAC
1,8	I-IUPAC
-	I-IUPAC
bc	I-IUPAC
]	I-IUPAC
thiophene	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
p	I-IUPAC
-	I-IUPAC
toluenesulfonate	I-IUPAC
(	O
17	O
)	O
also	O
has	O
high	O
kappa	O
opioid	O
receptor	O
affinity	O
and	O
selectivity	O
(	O
kappa	O
Ki	O
=	O
4.65	O
nM	O
,	O
mu	O
/	O
kappa	O
=	O
109	O
)	O
.	O
Reaction	O
of	O
2	O
with	O
sodium	O
azide	O
,	O
ceric	O
ammonium	O
nitrate	O
,	O
and	O
acetonitrile	O
-	O
methanol	O
or	O
water	O
afforded	O
the	O
5	B-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
1	I-PARTIUPAC
-	I-PARTIUPAC
hydroxy	I-PARTIUPAC
-	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
azidoethyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
(	O
10	O
)	O
and	O
5	B-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
azidoethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridines	I-IUPAC
(	O
11	O
)	O
.	O
The	O
results	O
indicate	O
that	O
compounds	O
6	O
and	O
11	O
have	O
animal	O
behavioral	O
pharmacology	O
similar	O
to	O
the	O
methylenedioxy	O
compounds	O
1	O
and	O
2	O
,	O
but	O
that	O
they	O
do	O
not	O
induce	O
the	O
serotonin	O
neurotoxicity	O
that	O
has	O
been	O
observed	O
for	O
the	O
latter	O
two	O
drugs	O
.	O
Synthesis	O
of	O
new	O
analogues	O
of	O
1	O
,	O
modified	O
only	O
in	O
the	O
heterocyclic	O
moiety	O
(	O
five	O
-	O
,	O
six	O
-	O
,	O
or	O
seven	O
-	O
membered	O
rings	O
with	O
NH	O
,	O
S	O
,	O
O	O
,	O
and	O
CH2	O
substituents	O
)	O
,	O
gave	O
compounds	O
varying	O
from	O
4	O
-	O
fold	O
higher	O
potency	O
(	B-IUPAC
2	I-IUPAC
-	I-IUPAC
iminothiazole	I-IUPAC
analogue	O
10	O
)	O
to	O
&	O
gt	O
;	O
6000	O
-	O
fold	O
less	O
active	O
than	O
(	B-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
nicotine	I-IUPAC
.	O
It	O
was	O
consequently	O
revealed	O
that	O
the	O
benzyl	O
ester	O
part	O
was	O
easily	O
hydrolyzed	O
to	O
produce	O
the	O
inactive	O
acid	O
analog	O
.	O
A	O
series	O
of	O
functionalized	O
congeners	O
of	O
1,3	B-IUPAC
-	I-IUPAC
dialkylxanthines	I-IUPAC
has	O
been	O
prepared	O
as	O
adenosine	O
receptor	O
antagonists	O
.	O
A	O
series	O
of	O
eight	O
previously	O
undescribed	O
2,4	B-IUPAC
-	I-IUPAC
diaminothieno	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
analogues	B-MODIFIER
of	O
the	O
potent	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
inhibitors	O
trimetrexate	O
(	O
TMQ	O
)	O
and	O
piritrexim	O
(	O
PTX	O
)	O
were	O
synthesized	O
as	O
potential	O
drugs	O
against	O
Pneumocystis	O
carinii	O
and	O
Toxoplasma	O
gondii	O
,	O
which	O
are	O
major	O
causes	O
of	O
severe	O
opportunistic	O
infections	O
in	O
AIDS	O
patients	O
.	O
The	O
pharmacological	O
/	O
pharmaceutical	O
properties	O
of	O
four	O
compounds	O
(	O
4	O
,	O
RHPS4	O
)	O
,	O
(	O
5	O
,	O
IH383	O
)	O
,	O
(	O
6	O
,	O
RHPS16	O
)	O
,	O
and	O
(	O
17	O
,	O
RHPS19	O
)	O
were	O
measured	O
to	O
assess	O
their	O
clinical	O
potential	O
as	O
DNA	O
G	O
-	O
quadruplex	O
-	O
stabilizing	O
/	O
telomerase	O
inhibitory	O
agents	O
.	O
Reaction	O
of	O
5,6,7,8	B-IUPAC
-	I-IUPAC
tetrahydrofolic	I-IUPAC
acid	I-IUPAC
(	O
THF	O
,	O
7	O
)	O
with	O
phosgene	O
,	O
thiophosgene	O
,	O
and	O
cyanogen	O
bromide	O
gave	O
the	O
bridged	O
derivatives	O
,	O
5,10	O
-	O
(	O
CO	O
)	O
-	O
THF	O
(	O
8	O
)	O
,	O
5,10	O
-	O
(	O
CS	O
)	O
-	O
THF	O
(	O
9	O
)	O
,	O
and	O
5,10	O
-	O
(	O
C	O
=	O
NH	O
)	O
-	O
THF	O
(	O
11	O
)	O
,	O
respectively	O
.	O
Further	O
,	O
both	O
17c	O
and	O
26	O
displayed	O
high	O
intrinsic	O
activity	O
in	O
stimulating	O
the	O
release	O
of	O
[	O
(	O
3	O
)	O
H	O
]	O
dopamine	O
from	O
striatal	O
synaptosomes	O
;	O
however	O
,	O
only	O
17c	O
was	O
effective	O
at	O
stimulating	O
the	O
release	O
of	O
[	O
(	O
3	O
)	O
H	O
]	O
acetylcholine	O
from	O
cortical	O
synaptosomes	O
,	O
suggesting	O
differential	O
selectivity	O
.	O
Pomeranz	O
-	O
Fritsch	O
condensation	O
followed	O
by	O
borohydride	O
reduction	O
and	O
acid	O
-	O
catalyzed	O
cyclization	O
led	O
smoothly	O
to	O
4	B-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5,8	I-IUPAC
-	I-IUPAC
dimethoxy	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydroisoquinoline	I-IUPAC
.	O
A	O
series	O
of	O
N	B-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
alkynyl	I-IUPAC
derivatives	B-MODIFIER
of	O
adenosine	O
(	O
Ado	O
)	O
have	O
been	O
synthesized	O
and	O
evaluated	O
for	O
their	O
affinity	O
at	O
human	O
A	O
(	O
1	O
)	O
,	O
A	O
(	O
2A	O
)	O
,	O
and	O
A	O
(	O
3	O
)	O
receptors	O
and	O
for	O
their	O
potency	O
at	O
A	O
(	O
2B	O
)	O
adenosine	O
receptor	O
subtypes	O
.	O
Amino	O
acid	O
analysis	O
subsequent	O
to	O
acid	O
hydrolysis	O
demonstrated	O
that	O
Met	O
had	O
been	O
selectively	O
alkylated	O
by	O
the	O
O'	B-IUPAC
-	I-IUPAC
(	I-IUPAC
epoxyalkyl	I-IUPAC
)	I-IUPAC
tyrosine	I-IUPAC
derivative	B-MODIFIER
.	O
administration	O
of	O
the	O
same	O
dose	O
.	O
On	O
the	O
basis	O
of	O
the	O
criteria	O
of	O
molecular	O
mass	O
,	O
RP	O
-	O
HPLC	O
elution	O
time	O
,	O
sequence	O
analysis	O
,	O
and	O
somatostatin	O
receptor	O
binding	O
affinity	O
,	O
our	O
synthetic	O
octreotide	O
is	O
identical	O
to	O
commercially	O
available	O
octreotide	O
.	O
A	O
series	O
of	O
(	B-IUPAC
beta	I-IUPAC
-	I-IUPAC
aminoethyl	I-IUPAC
)	I-IUPAC
indolones	I-IUPAC
and	O
related	O
compounds	O
was	O
synthesized	O
and	O
evaluated	O
in	O
vitro	O
as	O
peripheral	O
prejunctional	O
dopaminergic	O
agonists	O
in	O
the	O
field	O
-	O
stimulated	O
isolated	O
perfused	O
rabbit	O
ear	O
artery	O
.	O
Analogue	O
3	O
was	O
a	O
good	O
substrate	O
for	O
human	O
folylpolyglutamate	O
synthetase	O
(	O
FPGS	O
)	O
derived	O
from	O
CCRF	O
-	O
CEM	O
cells	O
(	O
Km	O
8.5	O
microM	O
)	O
.	O
The	O
5,8	B-IUPAC
-	I-IUPAC
dideaza	I-IUPAC
analogues	B-MODIFIER
were	O
prepared	O
from	O
methyl	B-IUPAC
2	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminobenzoyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
phthalimidopentanoate	I-IUPAC
and	O
2	B-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
diaminoquinazoline	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
carbonitriles	I-IUPAC
.	O
In	O
this	O
cisplatin	O
-	O
sensitive	O
cell	O
line	O
the	O
complexes	O
containing	O
cyclohexane	B-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
diamine	I-IUPAC
(	O
chxn	O
)	O
displayed	O
a	O
high	O
activity	O
in	O
comparison	O
to	O
the	O
diammine	B-IUPAC
and	O
ethane	B-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
diamine	I-IUPAC
counterparts	O
.	O
The	O
potency	O
of	O
13	O
against	O
P	O
.	O
The	O
synthesis	O
of	O
ethyl	B-IUPAC
or	O
methyl	B-IUPAC
4	B-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
or	O
unsubstituted	B-MODIFIER
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
pyrimidinecarboxylates	I-IUPAC
10-20	O
,	O
which	O
is	O
mainly	O
carried	O
out	O
by	O
reaction	O
of	O
ethyl	B-IUPAC
or	O
methyl	B-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
methylene	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
oxoalkanoates	I-IUPAC
with	O
1,1	B-IUPAC
-	I-IUPAC
dimethylguanidine	I-IUPAC
,	O
is	O
described	O
.	O
Optimization	O
led	O
to	O
the	O
5	B-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
derivative	B-MODIFIER
(	O
53	O
)	O
,	O
which	O
is	O
the	O
most	O
potent	O
and	O
selective	O
glycine	O
/	O
NMDA	O
antagonist	O
to	O
date	O
(	O
IC50	O
vs	O
[	O
3H	O
]	O
glycine	O
binding	O
,	O
32	O
nM	O
;	O
IC50	O
's	O
for	O
other	O
excitatory	O
amino	O
acid	O
receptor	O
sites	O
,	O
greater	O
than	O
100	O
microM	O
)	O
.	O
Condensation	O
of	O
4	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
N10	I-IUPAC
-	I-IUPAC
formylpteroic	I-IUPAC
acid	I-IUPAC
(	O
fAPA	O
)	O
with	O
dimethyl	B-IUPAC
-	I-IUPAC
DL	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methyleneglutamate	I-IUPAC
by	O
the	O
mixed	O
carboxylic	O
-	O
carbonic	O
anhydride	O
method	O
yielded	O
N	B-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
deoxypteroyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
DL	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methyleneglutamic	I-IUPAC
acid	I-IUPAC
(	O
gamma	O
-	O
methyleneAMT	O
)	O
.	O
Comparison	O
of	O
both	O
the	O
sigma	O
receptor	O
affinities	O
and	O
nitrogen	O
atom	O
geometry	O
of	O
the	O
compounds	O
revealed	O
that	O
a	O
gauche	O
relation	O
of	O
the	O
nitrogen	O
atoms	O
of	O
cis	B-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
cyclohexanediamines	I-IUPAC
is	O
not	O
imperative	O
for	O
high	O
affinity	O
as	O
we	O
had	O
previously	O
thought	O
.	O
Esterification	O
of	O
2a	O
with	O
isobutylene	O
afforded	O
tert	B-IUPAC
-	I-IUPAC
butyl	I-IUPAC
3	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
carbobenzoxy	I-IUPAC
-	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
diaminopropionate	I-IUPAC
(	O
3a	O
)	O
,	O
which	O
was	O
then	O
blocked	O
at	O
the	O
2	O
position	O
with	O
the	O
tert	B-IUPAC
-	I-IUPAC
butoxycarbonyl	I-IUPAC
(	O
Boc	O
)	O
group	B-MODIFIER
to	O
give	O
tert	B-IUPAC
-	I-IUPAC
butyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butoxycarbonyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
carbobenzoxy	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
propionate	I-IUPAC
(	O
4	O
)	O
.	O
The	O
primary	O
sulfonamides	O
were	O
reversible	O
noncompetitive	O
inhibitors	O
of	O
carbonic	O
anhydrase	O
,	O
with	O
no	O
effect	O
on	O
IOP	O
after	O
topical	O
administration	O
.	O
Hydrophobic	O
clustering	O
of	O
the	O
side	O
chains	O
of	O
Tyr	O
(	O
4	O
)	O
,	O
Phe	O
(	O
5	O
)	O
,	O
Ile	O
(	O
8	O
)	O
,	O
and	O
Trp	O
(	O
10	O
)	O
is	O
observed	O
.	O
High	O
affinity	O
was	O
found	O
in	O
some	O
cycloalkyl	B-MODIFIER
-	I-MODIFIER
annelated	I-MODIFIER
[	B-IUPAC
1,2,4	I-IUPAC
]	I-IUPAC
triazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
5	I-IUPAC
(	I-IUPAC
6H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
and	O
in	O
some	O
7,8,9,10	B-IUPAC
-	I-IUPAC
tetrahydropyrido	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
e	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,2,4	I-IUPAC
]	I-IUPAC
triazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
5	I-IUPAC
(	I-IUPAC
6H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
,	O
in	O
which	O
the	O
degree	O
of	O
activity	O
was	O
strongly	O
dependent	O
on	O
the	O
N	O
-	O
substituent	O
in	O
the	O
9	O
-	O
position	O
.	O
The	O
"	O
pharmacophore	O
"	O
for	O
selective	O
dopamine	O
D	O
-	O
1	O
antagonist	O
activity	O
appears	O
to	O
be	O
a	O
tertiary	O
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenethylamine	I-IUPAC
.	O
It	O
is	O
suggested	O
that	O
the	O
greater	O
conformational	O
flexibility	O
of	O
the	O
side	O
chain	O
allows	O
II	O
to	O
achieve	O
a	O
conformation	O
inaccessible	O
to	O
pirenzepine	O
,	O
which	O
allows	O
it	O
to	O
bind	O
preferentially	O
to	O
M2	O
receptors	O
.	O
Most	O
of	O
the	O
tested	O
compounds	O
19-31	O
proved	O
to	O
be	O
much	O
more	O
active	O
than	O
THA	O
in	O
reversing	O
the	O
neuromuscular	O
blockade	O
induced	O
by	O
d	O
-	O
tubocurarine	O
.	O
Compounds	O
were	O
evaluated	O
on	O
rat	O
cortical	O
tissue	O
for	O
their	O
ability	O
to	O
inhibit	O
the	O
binding	O
of	O
radioligands	O
selective	O
for	O
AMPA	O
(	O
[	O
3H	O
]	O
AMPA	O
)	O
,	O
NMDA	O
(	O
[	O
3H	O
]	O
CGS	O
19755	O
)	O
,	O
and	O
kainic	O
acid	O
(	O
[	O
3H	O
]	O
-	O
kainic	O
acid	O
)	O
receptors	O
and	O
for	O
their	O
ability	O
to	O
inhibit	O
depolarizations	O
induced	O
by	O
AMPA	O
(	O
40	O
microM	O
)	O
,	O
NMDA	O
(	O
40	O
microM	O
)	O
,	O
and	O
kainic	O
acid	O
(	O
10	O
microM	O
)	O
.	O
Pharmacological	O
evaluation	O
of	O
these	O
compounds	O
demonstrated	O
central	O
nervous	O
system	O
depressant	O
activity	O
,	O
potential	O
anticonvulsant	O
properties	O
,	O
and	O
a	O
low	O
order	O
of	O
acute	O
toxicity	O
.	O
As	O
shown	O
by	O
structure	O
-	O
activity	O
relationship	O
studies	O
in	O
8	B-IUPAC
-	I-IUPAC
(	I-IUPAC
substituted	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydroisoquinolines	I-IUPAC
,	O
the	O
most	O
important	O
structural	O
requirement	O
for	O
a	O
marked	O
antidepressant	O
action	O
is	O
the	O
presence	O
of	O
an	O
ureido	B-IUPAC
,	O
(	B-IUPAC
alkoxycarbonyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
,	O
or	O
[	B-IUPAC
(	I-IUPAC
alkylamino	I-IUPAC
)	I-IUPAC
acyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
group	B-MODIFIER
attached	O
to	O
the	O
isoquinoline	O
skeleton	O
in	O
position	O
8	O
.	O
Qualitative	O
structure	O
-	O
activity	O
relationships	O
within	O
this	O
series	O
were	O
explored	O
through	O
modifications	O
of	O
the	O
three	O
major	O
structural	O
units	O
of	O
dexoxadrol	O
,	O
the	O
piperidine	O
,	O
1,3	B-IUPAC
-	I-IUPAC
dioxolane	I-IUPAC
,	O
and	O
aromatic	O
rings	O
of	O
the	O
molecule	O
.	O
Acetate	O
salt	O
of	O
2	B-IUPAC
-	I-IUPAC
[	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amidinophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
furan	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
imidazo	I-IUPAC
[	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
carboxamidine	I-IUPAC
(	O
8a	O
)	O
was	O
obtained	O
from	O
4a	O
,	O
through	O
the	O
bis	B-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
acetoxyamidoxime	I-IUPAC
followed	O
by	O
hydrogenation	O
in	O
a	O
mixture	O
of	O
ethanol	O
/	O
ethyl	O
acetate	O
.	O
aureus	O
ATCC	O
29213	O
is	O
0.008	O
microgram	O
/	O
mL	O
.	O
Recently	O
,	O
we	O
have	O
discovered	O
that	O
PATs	O
also	O
bind	O
with	O
high	O
affinity	O
to	O
the	O
[	O
(	O
3	O
)	O
H	O
]	O
mepyramine	O
-	O
labeled	O
H	O
(	O
1	O
)	O
receptor	O
in	O
rat	O
and	O
guinea	O
pig	O
brain	O
.	O
A	O
series	O
of	O
analogues	O
and	O
homologues	O
of	O
N1	B-IUPAC
,	I-IUPAC
N12	I-IUPAC
-	I-IUPAC
diethylspermine	I-IUPAC
(	O
DESPM	O
)	O
was	O
synthesized	O
,	O
and	O
their	O
biological	O
properties	O
were	O
evaluated	O
.	O
A	O
number	O
of	O
compounds	O
(	O
1a	O
,	O
b	O
,	O
2a	O
-	O
c	O
,	O
f	O
,	O
3f	O
+	O
4d	O
)	O
showed	O
significant	O
cytotoxicity	O
to	O
cancer	O
cells	O
,	O
with	O
4	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosyl	I-IUPAC
)	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
1b	O
)	O
being	O
the	O
most	O
potent	O
proliferation	O
inhibitor	O
(	O
EC	O
(	O
50	O
)	O
:	O
0.06-0.08	O
microM	O
)	O
to	O
all	O
types	O
of	O
cells	O
tested	O
.	O
7	B-IUPAC
-	I-IUPAC
Oxa	I-IUPAC
-	I-IUPAC
7,8	I-IUPAC
-	I-IUPAC
dihydroretinoids	I-IUPAC
(	O
5	O
,	O
6	O
)	O
were	O
prepared	O
by	O
O	O
-	O
alkylation	O
of	O
phenoxides	O
by	O
methyl	B-IUPAC
8	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
3,7	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
2,4,6	I-IUPAC
-	I-IUPAC
octatrienoate	I-IUPAC
.	O
Octreotide	O
,	O
an	O
analogue	O
of	O
the	O
hormone	O
somatostatin	O
,	O
has	O
applications	O
as	O
a	O
therapeutic	O
and	O
imaging	O
agent	O
for	O
somatostatin	O
-	O
positive	O
tumors	O
.	O
Single	O
-	O
point	O
replacement	O
of	O
each	O
amino	O
acid	O
by	O
alanine	O
led	O
to	O
the	O
identification	O
of	O
[	O
Ala8	O
]	O
-	O
,	O
[	O
Ala9	O
]	O
-	O
,	O
[	O
Ala15	O
]	O
-	O
(	O
Felix	O
et	O
al.	O
Peptides	O
1986	O
1986	O
,	O
481	O
)	O
,	O
[	O
Ala22	O
]	O
-	O
,	O
and	O
[	O
Ala28	O
,	O
Nle27	O
]	O
-	O
hGHRH	O
(	O
1-29	O
)	O
-	O
NH2	O
as	O
being	O
2-6	O
times	O
more	O
potent	O
than	O
hGHRH	O
(	O
1-40	O
)	O
-	O
OH	O
(	O
standard	O
)	O
in	O
vitro	O
.	O
In	O
the	O
3	O
-	O
day	O
immature	O
mouse	O
antiuterotrophic	O
assay	O
,	O
five	O
DTACs	O
with	O
either	O
a	O
methoxy	B-IUPAC
(	O
5a	O
)	O
,	O
benzyloxy	B-IUPAC
(	O
4d	O
,	O
5c	O
)	O
,	O
or	O
(	B-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
ethoxy	I-IUPAC
(	O
7a	O
,	O
7b	O
)	O
central	O
ring	O
side	O
chain	O
produced	O
significant	O
decreases	O
in	O
uterine	O
weight	O
at	O
doses	O
up	O
to	O
750	O
micrograms	O
.	O
The	O
results	O
of	O
radiosensitizing	O
activity	O
of	O
these	O
agents	O
against	O
hypoxic	O
Chinese	O
hamster	O
cells	O
(	O
V	O
-	O
79	O
)	O
indicated	O
that	O
2,4	B-IUPAC
-	I-IUPAC
dinitroimidazoles	I-IUPAC
were	O
better	O
sensitizers	O
than	O
the	O
nitroimidazo	B-IUPAC
[	I-IUPAC
2,1	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
oxazoles	I-IUPAC
,	O
suggesting	O
the	O
necessity	O
of	O
the	O
2	B-IUPAC
-	I-IUPAC
nitro	I-IUPAC
function	B-MODIFIER
in	O
the	O
molecule	O
.	O
3,4	O
-	O
Dihydro	O
-	O
2	O
(	O
1H	O
)	O
-	O
quinolones	O
,	O
evolved	O
from	O
2	B-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
,	I-IUPAC
-	I-IUPAC
tetrahydroquinolines	I-IUPAC
and	O
3	B-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
quinolones	I-IUPAC
,	O
have	O
been	O
synthesized	O
and	O
evaluated	O
in	O
vitro	O
for	O
antagonist	O
activity	O
at	O
the	O
glycine	O
site	O
on	O
the	O
NMDA	O
receptor	O
and	O
for	O
AMPA	O
[	O
(	B-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolepropionic	I-IUPAC
acid	I-IUPAC
]	O
antagonist	O
activity	O
.	O
High	O
affinity	O
for	O
both	O
sigma	O
1	O
and	O
sigma	O
2	O
binding	O
sites	O
was	O
achieved	O
with	O
these	O
compounds	O
.	O
Structure	O
-	O
activity	O
relationships	O
showing	O
the	O
effect	O
of	O
a	O
substituent	O
(	O
Me	O
,	O
CF3	O
,	O
Cl	O
,	O
NO2	O
,	O
Ph	O
)	O
at	O
the	O
3	O
-	O
or	O
6	O
-	O
position	O
of	O
a	O
C	O
-	O
4	O
2	B-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
moiety	B-MODIFIER
and	O
a	O
variety	O
of	O
ester	O
substituents	O
(	O
Me	O
,	O
Et	O
,	O
i	O
-	O
Pr	O
,	O
PhCH2CH2	O
-	O
)	O
upon	O
calcium	O
channel	O
modulation	O
are	O
described	O
.	O
When	O
tested	O
against	O
herpes	O
simplex	O
virus	O
type	O
1	O
,	O
only	O
9	O
was	O
active	O
with	O
an	O
IC50	O
=	O
8	O
microM	O
.	O
In	O
a	O
NOESY	O
experiment	O
,	O
cross	O
-	O
peaks	O
were	O
identified	O
between	O
both	O
the	O
aromatic	O
H9	O
proton	O
and	O
the	O
ethylidine	O
methyl	O
protons	O
of	O
tomaymycin	O
and	O
two	O
different	O
adenine	O
H2	O
protons	O
of	O
d	O
(	O
ATGCAT	O
)	O
2	O
.	O
These	O
data	O
confirm	O
that	O
the	O
distance	O
between	O
the	O
Dmt	O
-	O
Tic	O
pharmacophore	O
and	O
a	O
third	O
aromatic	O
nucleus	O
is	O
an	O
important	O
criterion	O
in	O
converting	O
Dmt	O
-	O
Tic	O
from	O
a	O
highly	O
potent	O
delta	O
-	O
antagonist	O
into	O
a	O
potent	O
delta	O
-	O
agonist	O
or	O
into	O
ligands	O
with	O
mixed	O
delta	O
-	O
and	O
mu	O
-	O
opioid	O
properties	O
.	O
Optimal	O
activity	O
was	O
attained	O
when	O
the	O
two	O
nipecotoyl	O
ring	O
N	O
atoms	O
were	O
connected	O
by	O
an	O
aralkyl	B-IUPAC
group	B-MODIFIER
,	O
and	O
separated	O
by	O
approximately	O
7	O
A	O
.	O
Deprotection	O
of	O
ethyl	B-IUPAC
3	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
3,5	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
toluoyl	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
erythro	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
)	I-IUPAC
pyrr	I-IUPAC
ole	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
(	O
12	O
)	O
using	O
sodium	O
ethoxide	O
furnished	O
ethyl	B-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
erythro	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
cyanopyrrole	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
late	I-IUPAC
(	O
14	O
)	O
which	O
served	O
as	O
the	O
starting	O
material	O
for	O
the	O
preparation	O
of	O
4	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dideoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
glycero	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
)	I-IUPAC
pyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyridazin	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
20	O
)	O
.	O
The	O
protected	O
peptide	O
was	O
cleaved	O
from	O
the	O
resin	O
by	O
aminolysis	O
with	O
threoninol	O
and	O
purified	O
by	O
semipreparative	O
RP	O
-	O
HPLC	O
.	O
Nicotinates	O
7b	O
,	O
d	O
-	O
g	O
were	O
converted	O
into	O
their	O
corresponding	O
2,4	B-IUPAC
-	I-IUPAC
diaminopyrido	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
12b	O
,	O
d	O
-	O
g	O
in	O
five	O
steps	O
,	O
via	O
reduction	O
,	O
protection	O
,	O
oxidation	O
,	O
condensation	O
with	O
guanidine	O
,	O
and	O
deprotection	O
.	O
When	O
acidolysis	O
was	O
preceded	O
by	O
catalytic	O
hydrogenation	O
,	O
the	O
final	O
product	O
was	O
the	O
corresponding	O
(	O
6R	O
,	O
6S	O
)	O
-	O
tetrahydro	O
derivative	O
2	O
.	O
The	O
requisite	O
intermediate	O
gamma	B-IUPAC
-	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
4	I-IUPAC
-	I-IUPAC
cyanoglutamate	I-IUPAC
,	O
as	O
a	O
DL	O
-	O
threo	O
/	O
DL	O
-	O
erythro	O
mixture	O
,	O
was	O
prepared	O
from	O
methyl	B-IUPAC
N	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
Boc	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
tosyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
serinate	I-IUPAC
by	O
reaction	O
with	O
sodium	B-IUPAC
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
cyanoacetate	I-IUPAC
followed	O
by	O
mild	O
trifluoroacetic	O
treatment	O
to	O
selectively	O
remove	O
the	O
Boc	O
group	O
.	O
This	O
manuscript	O
describes	O
our	O
synthetic	O
endeavors	O
around	O
4	O
,	O
5	O
,	O
and	O
7	O
mono	O
-	O
and	O
disubstitutions	O
of	O
1	O
and	O
discusses	O
related	O
HIV	O
-	O
1	O
inhibitory	O
structure	O
-	O
activity	O
relationships	O
.	O
3,5	B-IUPAC
-	I-IUPAC
Dimethylacetaminophen	I-IUPAC
was	O
slightly	O
more	O
nephrotoxic	O
but	O
showed	O
a	O
similar	O
hepatotoxicity	O
to	O
acetaminophen	O
.	O
The	O
in	O
vivo	O
potency	O
of	O
26	O
was	O
at	O
least	O
10	O
-	O
fold	O
less	O
than	O
that	O
of	O
monocyclic	O
cyclo	O
(	O
1-3	O
)	O
[	O
Ac	O
-	O
DAsp	O
(	O
1	O
)	O
,	O
DCpa	O
(	O
2	O
)	O
,	O
DLys	O
(	O
3	O
)	O
,	O
DNal	O
(	O
6	O
)	O
,	O
DAla	O
(	O
10	O
)	O
]	O
GnRH	O
(	O
5	O
)	O
;	O
this	O
suggested	O
the	O
existence	O
of	O
unfavorable	O
interactions	O
between	O
the	O
now	O
optimized	O
and	O
constrained	O
(	O
1-3	O
)	O
and	O
(	O
4-10	O
)	O
cyclic	O
moieties	O
that	O
must	O
interact	O
as	O
originally	O
hypothesized	O
.	O
They	O
combine	O
10	O
different	O
N	O
-	O
protecting	O
groups	O
(	O
R1	O
)	O
,	O
3	O
amino	O
acids	O
residues	O
in	O
P1	O
(	O
AA	O
)	O
,	O
and	O
44	O
distinct	O
substituents	O
on	O
the	O
alpha	O
-	O
keto	O
amide	O
nitrogen	O
(	O
R2	O
)	O
.	O
The	O
position	O
of	O
the	O
oxygen	O
atom	O
and	O
the	O
position	O
of	O
the	O
spiroconnection	O
with	O
the	O
4	O
-	O
position	O
of	O
the	O
piperidine	O
ring	O
were	O
varied	O
,	O
and	O
only	O
compounds	O
in	O
which	O
both	O
the	O
benzene	O
ring	O
and	O
the	O
heteroatom	O
are	O
attached	O
directly	O
to	O
the	O
piperidine	O
ring	O
retain	O
high	O
affinity	O
and	O
selectivity	O
for	O
sigma	O
2	O
binding	O
sites	O
(	O
e.g.	O
,	O
3,4	B-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
1'	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
spiro	I-IUPAC
[	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
'	I-IUPAC
-	I-IUPAC
piperidine	I-IUPAC
]	I-IUPAC
:	O
IC50	O
(	O
sigma	O
1	O
)	O
=	O
53	O
nM	O
,	O
IC50	O
(	O
sigma	O
2	O
)	O
=	O
0.9	O
nM	O
)	O
.	O
7	B-IUPAC
-	I-IUPAC
(	I-IUPAC
2,3,5	I-IUPAC
-	I-IUPAC
Trimethylphenoxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3,5	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
2,4,6	I-IUPAC
-	I-IUPAC
octatrienoic	I-IUPAC
acid	I-IUPAC
(	O
6b	O
)	O
was	O
the	O
most	O
active	O
of	O
the	O
7	O
-	O
oxa	O
-	O
7,8	O
-	O
dihydro	O
-	O
RAs	O
in	O
inhibiting	O
DMBA	O
-	O
initiated	O
and	O
TPA	O
-	O
promoted	O
mouse	O
-	O
skin	O
papillomas	O
.	O
With	O
the	O
exception	O
of	O
3e	O
and	O
3f	O
,	O
which	O
have	O
no	O
substituent	O
on	O
the	O
2beta	B-IUPAC
-	I-IUPAC
(	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
isoxazole	I-IUPAC
)	I-IUPAC
ring	B-MODIFIER
,	O
all	O
compounds	O
were	O
selective	O
for	O
the	O
DAT	O
relative	O
to	O
the	O
5	O
-	O
HTT	O
and	O
NET	O
.	O
The	O
previously	O
reported	O
diphenyl	B-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
prolylpyrrolidine	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
R	I-IUPAC
,	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
phosphonate	I-IUPAC
(	O
5	O
)	O
was	O
used	O
as	O
a	O
lead	O
compound	O
for	O
the	O
development	O
of	O
potent	O
and	O
irreversible	O
inhibitors	O
of	O
dipeptidyl	B-IUPAC
peptidase	I-IUPAC
IV	I-IUPAC
(	O
DPP	O
IV	O
,	O
EC	O
3.4.14.5	O
)	O
.	O
Two	O
approaches	O
for	O
the	O
preparation	O
of	O
iodinated	O
versions	O
of	O
these	O
prostaglandins	O
were	O
evaluated	O
:	O
(	O
1	O
)	O
iodination	O
of	O
a	O
phenyl	O
azide	O
bearing	O
an	O
activating	O
hydroxyl	O
group	O
and	O
(	O
2	O
)	O
iodination	O
of	O
an	O
aniline	O
precursor	O
to	O
the	O
phenyl	O
azide	O
group	O
and	O
subsequent	O
conversion	O
of	O
the	O
aniline	O
to	O
the	O
phenyl	O
azide	O
.	O
When	O
administered	O
by	O
injection	O
twice	O
a	O
day	O
at	O
45	O
mg	O
/	O
kg	O
for	O
11	O
consecutive	O
days	O
,	O
both	O
compounds	O
showed	O
prolonged	O
survival	O
time	O
(	O
T	O
/	O
C	O
=	O
142-145%	O
)	O
,	O
thus	O
demonstrating	O
efficacy	O
against	O
ras	O
oncogene	O
-	O
containing	O
tumors	O
in	O
vivo	O
.	O
Both	O
alkyl	O
and	O
aryl	O
substituents	O
were	O
examined	O
.	O
Our	O
synthetic	O
route	O
provided	O
both	O
enantiomers	O
of	O
11a	O
and	O
11b	O
with	O
greater	O
than	O
97%	O
enantiomeric	O
purity	O
based	O
upon	O
evaluation	O
of	O
the	O
NMR	O
spectra	O
of	O
their	O
Mosher	O
's	O
acid	O
derivatives	O
.	O
Among	O
the	O
synthesized	O
compounds	O
,	O
N	B-IUPAC
-	I-IUPAC
(	I-IUPAC
7	I-IUPAC
-	I-IUPAC
alkoxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxochroman	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
amide	I-IUPAC
derivatives	B-MODIFIER
showed	O
potent	O
ACAT	O
inhibitory	O
activity	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
They	O
also	O
exhibited	O
the	O
promotional	O
effects	O
on	O
recovery	O
from	O
coma	O
at	O
a	O
dose	O
of	O
100	O
mg	O
/	O
kg	O
po	O
.	O
At	O
cloned	O
metabotropic	O
Glu	O
receptors	O
mGluR1alpha	O
(	O
group	O
I	O
)	O
,	O
mGluR2	O
(	O
group	O
II	O
)	O
,	O
and	O
mGluR4a	O
(	O
group	O
III	O
)	O
,	O
neither	O
6	O
nor	O
7	O
showed	O
significant	O
agonist	O
or	O
antagonist	O
effects	O
.	O
The	O
3	B-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
naphthoyl	I-IUPAC
)	I-IUPAC
substituent	B-MODIFIER
of	O
7e	O
(	O
52%	O
)	O
also	O
supported	O
AE	O
activity	O
.	O
However	O
,	O
analysis	O
of	O
the	O
high	O
-	O
affinity	O
(	O
2R	O
,	O
3R	O
)	O
-	O
MePhe3	O
analog	O
revealed	O
a	O
strong	O
preference	O
for	O
a	O
single	O
side	O
chain	O
conformer	O
(	O
chi	O
1	O
approximately	O
60	O
degrees	O
)	O
.	O
Ester	O
cleavage	O
and	O
decarboxylation	O
at	O
C	O
-	O
10	O
were	O
accomplished	O
by	O
heating	O
with	O
sodium	O
cyanide	O
in	O
Me2SO	O
at	O
170-180	O
degrees	O
C	O
to	O
afford	O
the	O
2,4	B-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
8,10	I-IUPAC
-	I-IUPAC
dideazapteroic	I-IUPAC
acids	I-IUPAC
.	O
Among	O
the	O
unsaturated	O
acyclonucleosides	O
tested	O
,	O
9	B-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
propargyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chloropurine	I-IUPAC
(	O
3	O
)	O
,	O
9	B-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
propargyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
mercaptopurine	I-IUPAC
(	O
15	O
)	O
,	O
9	B-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
propargyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
azathioprine	I-IUPAC
(	O
17	O
)	O
,	O
and	O
angustmycin	O
A	O
analogue	O
10	O
showed	O
inhibition	O
of	O
cancer	O
cell	O
growth	O
,	O
but	O
only	O
at	O
a	O
minimal	O
level	O
,	O
and	O
17	O
also	O
showed	O
14%	O
cancer	O
cell	O
death	O
in	O
vitro	O
.	O
Since	O
thrombin	O
inhibitors	O
appear	O
to	O
be	O
effective	O
in	O
the	O
treatment	O
and	O
prevention	O
of	O
thrombotic	O
and	O
embolic	O
disorders	O
,	O
considerable	O
attention	O
has	O
been	O
focused	O
on	O
the	O
structure	O
and	O
interactions	O
of	O
this	O
enzyme	O
.	O
3	B-IUPAC
-	I-IUPAC
Bromoallopurinol	I-IUPAC
ribonucleoside	B-MODIFIER
(	O
6a	O
)	O
was	O
found	O
to	O
be	O
more	O
active	O
than	O
allopurinol	O
ribonucleoside	O
against	O
Leishmania	O
tropica	O
within	O
human	O
macrophages	O
in	O
vitro	O
.	O
Analogues	O
incorporating	O
pyrrolidine	O
in	O
lieu	O
of	O
piperidine	O
were	O
also	O
prepared	O
.	O
This	O
was	O
particularly	O
evident	O
in	O
the	O
8	B-IUPAC
-	I-IUPAC
methylquinazolinone	I-IUPAC
series	B-MODIFIER
(	O
IC50	O
values	O
0.13-0.27	O
microM	O
)	O
,	O
which	O
are	O
among	O
the	O
most	O
potent	O
PARP	O
inhibitors	O
reported	O
to	O
date	O
.	O
Three	O
of	O
these	O
compounds	O
-	O
8azaadenosine	B-IUPAC
(	O
4	O
)	O
,	O
8	B-IUPAC
-	I-IUPAC
aza	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylthio	I-IUPAC
)	I-IUPAC
purine	I-IUPAC
ribonucleoside	I-IUPAC
(	O
5	O
)	O
,	O
and	O
8	B-IUPAC
-	I-IUPAC
aza	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methoxy	I-IUPAC
)	I-IUPAC
purine	I-IUPAC
ribonucleoside	I-IUPAC
(	O
7	O
)	O
-	O
showed	O
borderline	O
activity	O
in	O
the	O
leukemia	O
L1210	O
system	O
.	O
The	O
replacement	O
of	O
piperazine	O
and	O
furan	O
units	O
of	O
prazosin	O
(	O
1	O
)	O
by	O
1	B-IUPAC
,	I-IUPAC
6	I-IUPAC
-	I-IUPAC
hexanediamine	I-IUPAC
and	O
phenyl	B-IUPAC
moieties	B-MODIFIER
,	O
respectively	O
,	O
affording	O
3-20	O
,	O
markedly	O
affected	O
both	O
affinity	O
and	O
selectivity	O
for	O
alpha1	O
-	O
adrenoreceptor	O
subtypes	O
in	O
functional	O
experiments	O
.	O
Most	O
of	O
the	O
analogs	O
displaced	O
[	O
3H	O
]	O
1	O
from	O
its	O
binding	O
sites	O
,	O
with	O
compounds	O
14	O
(	O
IC50	O
0.42	O
microM	O
)	O
and	O
15	O
(	O
IC50	O
0.88	O
microM	O
)	O
having	O
equivalent	O
potencies	O
to	O
1	O
(	O
IC50	O
0.59	O
microM	O
)	O
,	O
in	O
rat	O
brain	O
,	O
and	O
no	O
appreciable	O
activity	O
at	O
the	O
[	O
3H	O
]	O
TCP	O
or	O
[	O
3H	O
]	O
glycine	O
-	O
labeled	O
sites	O
.	O
N10	B-IUPAC
-	I-IUPAC
Propargylfolic	I-IUPAC
acid	I-IUPAC
(	O
2	O
)	O
,	O
which	O
is	O
the	O
closest	O
pteridine	O
analogue	O
of	O
the	O
thymidylate	O
synthase	O
inhibitor	O
N10	B-IUPAC
-	I-IUPAC
propargyl	I-IUPAC
-	I-IUPAC
5,8	I-IUPAC
-	I-IUPAC
dideazafolic	I-IUPAC
acid	I-IUPAC
(	O
PDDF	O
)	O
,	O
was	O
synthesized	O
starting	O
from	O
diethyl	B-IUPAC
[	I-IUPAC
p	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
propargylamino	I-IUPAC
)	I-IUPAC
benzoyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamate	I-IUPAC
(	O
5	O
)	O
and	O
N	B-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxopropyl	I-IUPAC
)	I-IUPAC
phthalimide	I-IUPAC
(	O
8	O
)	O
.	O
Both	O
(	B-PARTIUPAC
R	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
(	B-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
[	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoroacetyl	I-IUPAC
)	I-IUPAC
daunosaminyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5,12	I-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
azanaphthacene	I-IUPAC
-	I-IUPAC
6,11	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
were	O
inactive	O
ip	O
in	O
mice	O
carrying	O
the	O
P388	O
tumor	O
.	O
These	O
compounds	O
exhibited	O
significantly	O
potent	O
activity	O
upon	O
oral	O
administration	O
with	O
ED50	O
values	O
of	O
0.068-0.17	O
mg	O
/	O
kg	O
.	O
From	O
series	O
I	O
,	O
a	O
mixed	O
RAR	O
beta	O
-	O
gamma	O
agonist	O
with	O
potent	O
cellular	O
differentiating	O
activity	O
was	O
selected	O
for	O
development	O
as	O
a	O
topical	O
antiacne	O
agent	O
,	O
6	B-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
adamantyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methoxyphenyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthoic	I-IUPAC
acid	I-IUPAC
(	O
5	O
,	O
CD	O
271	O
)	O
[	O
Ki	O
(	O
RAR	O
alpha	O
)	O
=	O
1100	O
nM	O
,	O
Ki	O
-	O
(	O
RAR	O
beta	O
)	O
=	O
34	O
nM	O
,	O
Ki	O
(	O
RAR	O
gamma	O
)	O
=	O
130	O
nM	O
,	O
AC50	O
(	O
F9	O
)	O
=	O
37	O
nM	O
]	O
.	O
This	O
[	B-IUPAC
1,2,4	I-IUPAC
]	I-IUPAC
triazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
triazine	I-IUPAC
core	B-MODIFIER
structure	I-MODIFIER
has	O
now	O
been	O
improved	O
by	O
incorporating	O
various	O
piperazine	O
derivatives	O
.	O
The	O
general	O
requirement	O
of	O
acidity	O
for	O
high	O
affinity	O
binding	O
at	O
the	O
glycine	O
/	O
NMDA	O
site	O
is	O
supported	O
with	O
the	O
good	O
activity	O
of	O
the	O
other	O
3	B-PARTIUPAC
-	I-PARTIUPAC
nitro	I-PARTIUPAC
derivatives	B-MODIFIER
(	O
13-21	O
)	O
,	O
all	O
of	O
which	O
are	O
deprotonated	O
at	O
physiological	O
pH	O
.	O
All	O
three	O
compounds	O
fully	O
antagonized	O
the	O
effects	O
of	O
carbachol	O
at	O
the	O
M1	O
receptor	O
,	O
while	O
only	O
4d	O
completely	O
antagonized	O
carbachol	O
at	O
the	O
M2	O
receptor	O
.	O
Amination	O
of	O
9a	O
-	O
e	O
with	O
aqueous	O
chloramine	O
solution	O
afforded	O
the	O
corresponding	O
purine	B-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
sulfenamides	I-IUPAC
(	O
10	O
-	O
a	O
-	O
e	O
)	O
,	O
which	O
on	O
controlled	O
oxidation	O
with	O
3	B-IUPAC
-	I-IUPAC
chloroperoxbenzoic	I-IUPAC
acid	I-IUPAC
(	O
MCPBA	O
)	O
gave	O
the	O
respective	O
(	B-IUPAC
R	I-IUPAC
,	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
alkylpurine	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
sulfinamides	I-IUPAC
(	O
11a	O
-	O
e	O
)	O
.	O
The	O
nisoxetine	O
derivatives	O
8	O
(	O
rac	B-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylamino	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
naphthale	I-IUPAC
nesulfonamide	I-IUPAC
)	O
and	O
9	O
(	O
rac	B-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylamino	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
-	I-IUPAC
2,1	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
benzoxadiazole	I-IUPAC
)	O
and	O
especially	O
the	O
guanidine	O
derivative	O
4	O
(	O
1	B-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
butadienyl	I-IUPAC
)	I-IUPAC
benzyl	I-IUPAC
]	I-IUPAC
guanidinium	I-IUPAC
sulfate	I-IUPAC
)	O
which	O
are	O
characterized	O
by	O
intermediate	O
affinity	O
for	O
the	O
NET	O
(	O
IC	O
(	O
50	O
)	O
370-850	O
nM	O
)	O
caused	O
significant	O
and	O
nisoxetine	O
-	O
sensitive	O
cell	O
fluorescence	O
.	O
Of	O
the	O
compounds	O
examined	O
,	O
the	O
greatest	O
degree	O
of	O
activity	O
in	O
vitro	O
was	O
found	O
with	O
the	O
7	B-IUPAC
-	I-IUPAC
mercaptopyrazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
A	O
series	O
of	O
analogues	O
of	O
the	O
conformationally	O
restricted	O
delta	O
opioid	O
receptor	O
selective	O
tetrapeptide	O
Tyr	O
-	O
c	O
[	O
D	O
-	O
Cys	O
-	O
Phe	O
-	O
D	O
-	O
Pen	O
]	O
OH	O
(	O
JOM	O
13	O
)	O
was	O
prepared	O
in	O
which	O
the	O
conformationally	O
labile	O
Tyr	O
residue	O
was	O
replaced	O
with	O
several	O
less	O
flexible	O
tyrosine	O
analogues	O
.	O
Sugar	O
derivatives	O
1	O
and	O
6	O
were	O
also	O
condensed	O
with	O
benzoylacetone	O
to	O
give	O
14	O
and	O
18	O
,	O
with	O
acetoacetanilide	O
to	O
give	O
16	O
and	O
19	O
,	O
with	O
malononitrile	O
to	O
give	O
17	O
and	O
20	O
,	O
and	O
with	O
alpha	B-IUPAC
-	I-IUPAC
(	I-IUPAC
gamma	I-IUPAC
-	I-IUPAC
butyrolactonylidene	I-IUPAC
)	I-IUPAC
triphenylphosphorane	I-IUPAC
to	O
give	O
21	O
and	O
22	O
,	O
respectively	O
.	O
After	O
the	O
syn	O
diastereomers	O
were	O
found	O
to	O
have	O
the	O
highest	O
activity	O
in	O
these	O
preliminary	O
assays	O
,	O
the	O
N	O
-	O
alkylated	O
analogues	O
syn	B-IUPAC
-	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
2a	I-IUPAC
,	I-IUPAC
3,4	I-IUPAC
,	I-IUPAC
5	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
naphtho	I-IUPAC
[	I-IUPAC
1,8	I-IUPAC
-	I-IUPAC
bc	I-IUPAC
]	I-IUPAC
furan	I-IUPAC
(	O
4e	O
)	O
and	O
syn	B-IUPAC
-	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dipropyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
2a	I-IUPAC
,	I-IUPAC
3,4,5	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
naphtho	I-IUPAC
[	I-IUPAC
1	I-IUPAC
,	I-IUPAC
8	I-IUPAC
-	I-IUPAC
bc	I-IUPAC
]	I-IUPAC
furan	I-IUPAC
(	O
4f	O
)	O
were	O
prepared	O
and	O
assayed	O
for	O
their	O
affinities	O
at	O
[	O
3H	O
]	O
ketanserin	O
-	O
labeled	O
5	O
-	O
HT2A	O
and	O
[	O
3H	O
]	O
-	O
8	O
-	O
OH	O
-	O
DPAT	O
-	O
labeled	O
5	O
-	O
HT1A	O
sites	O
.	O
The	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
N	B-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
1,6	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
pyrimidinyl	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
benzoyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamic	I-IUPAC
acid	I-IUPAC
(	O
1	O
)	O
(	O
5	O
-	O
DACTHF	O
,	O
543U76	O
)	O
,	O
an	O
acyclic	O
analogue	O
of	O
5,6,7,8	B-IUPAC
-	I-IUPAC
tetrahydrofolic	I-IUPAC
acid	I-IUPAC
(	O
THFA	O
)	O
,	O
are	O
described	O
.	O
Analogue	O
4a	O
and	O
its	O
enantiomer	O
have	O
been	O
tritiated	O
at	O
C	O
-	O
1	O
and	O
both	O
were	O
found	O
to	O
be	O
activated	O
to	O
a	O
nucleotide	O
sugar	O
,	O
which	O
was	O
followed	O
by	O
incorporation	O
into	O
the	O
macromolecular	O
fraction	O
of	O
SW613	O
human	O
mammary	O
tumor	O
cells	O
in	O
vitro	O
.	O
The	O
synthesis	O
of	O
a	O
range	O
of	O
3	B-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyridinones	I-IUPAC
with	O
potential	O
for	O
the	O
chelation	O
of	O
iron	O
(	O
III	O
)	O
is	O
described	O
.	O
The	O
benzopyrans	O
have	O
thus	O
emerged	O
as	O
a	O
new	O
class	O
of	O
potent	O
antiestrogens	O
.	O
The	O
1	B-IUPAC
,	I-IUPAC
6	I-IUPAC
-	I-IUPAC
naphthyridin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
showed	O
broadly	O
similar	O
activity	O
to	O
the	O
analogous	B-MODIFIER
pyrido	B-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
7	I-IUPAC
(	I-IUPAC
8H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
,	O
whereas	O
the	O
1	B-IUPAC
,	I-IUPAC
8	I-IUPAC
-	I-IUPAC
naphthyridin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
were	O
at	O
least	O
10	O
(	O
3	O
)	O
-	O
fold	O
less	O
potent	O
.	O
At	O
A1	O
,	O
A2A	O
,	O
and	O
A3	O
receptors	O
however	O
the	O
optimum	O
occurs	O
with	O
four	O
methylene	O
groups	O
.	O
The	O
compounds	O
within	O
this	O
series	O
were	O
prepared	O
as	O
analogues	O
of	O
the	O
previously	O
described	O
1	B-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
piperidyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indoles	I-IUPAC
by	O
interchange	O
of	O
the	O
C	O
-	O
3	O
carbon	O
atom	O
and	O
the	O
nitrogen	O
atom	O
in	O
the	O
indole	O
nucleus	O
.	O
Receptor	O
-	O
binding	O
studies	O
with	O
specific	O
radiolabeled	O
ligands	O
indicate	O
that	O
the	O
specificity	O
conferred	O
by	O
the	O
site	O
of	O
fluorine	O
substituents	O
results	O
from	O
a	O
change	O
in	O
the	O
affinity	O
of	O
these	O
analogues	O
for	O
the	O
alpha	O
-	O
and	O
beta	O
-	O
adrenergic	O
receptors	O
.	O
;	O
Cheatham	O
,	O
S	O
.	O
A	O
series	O
of	O
new	O
S	B-IUPAC
-	I-IUPAC
adenosyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
homocysteine	I-IUPAC
(	O
AdoHcy	O
)	O
analogues	B-MODIFIER
with	O
modifications	O
to	O
amino	O
acid	O
and	O
nucleoside	O
moieties	O
was	O
prepared	O
via	O
condensation	O
of	O
appropriate	O
nucleoside	O
precursors	O
and	O
suitably	O
protected	O
L	O
-	O
homocystine	O
derivatives	O
.	O
Within	O
this	O
series	O
,	O
naphthalene	O
was	O
found	O
to	O
be	O
superior	O
to	O
other	O
groups	O
for	O
eliciting	O
antihyperglycemic	O
activity	O
,	O
including	O
the	O
p	B-IUPAC
-	I-IUPAC
alkoxyphenyl	I-IUPAC
group	B-MODIFIER
found	O
in	O
ciglitazone	O
,	O
a	O
prototypical	O
agent	O
for	O
this	O
activity	O
.	O
Phosphate	O
prodrugs	O
were	O
prepared	O
by	O
classical	O
phosphorylation	O
using	O
phosphorus	O
oxychloride	O
and	O
alternatively	O
by	O
using	O
a	O
phosphoramidite	O
method	O
.	O
In	O
an	O
effort	O
to	O
develop	O
selective	O
inhibitors	O
of	O
vesicular	O
acetylcholine	O
storage	O
,	O
we	O
have	O
synthesized	O
a	O
series	O
of	O
semirigid	O
vesamicol	O
receptor	O
ligands	O
based	O
on	O
the	O
structure	O
of	O
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phenylpiperidino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cyclohexanol	I-IUPAC
(	O
vesamicol	O
,	O
AH5183	O
,	O
1	O
)	O
.	O
These	O
compounds	O
were	O
tested	O
in	O
the	O
rat	O
passive	O
cutaneous	O
anaphylaxis	O
(	O
PCA	O
)	O
assay	O
.	O
Nuclear	O
Overhauser	O
(	O
NOE	O
)	O
studies	O
indicated	O
there	O
is	O
a	O
significant	O
rotamer	O
fraction	O
in	O
solution	O
where	O
the	O
pyridyl	O
nitrogen	O
is	O
oriented	O
above	O
the	O
1,4	B-IUPAC
-	I-IUPAC
dihydropyridine	I-IUPAC
ring	B-MODIFIER
,	O
irrespective	O
of	O
whether	O
a	O
substituent	O
is	O
located	O
at	O
the	O
3	O
-	O
or	O
6	O
-	O
position	O
.	O
[	O
3	O
-	O
(	O
1,4	O
-	O
Cyclohexadienyl	O
)	O
-	O
L	O
-	O
alanine	O
,	O
8	O
-	O
lysine	O
]	O
vasopressin	O
,	O
otherwise	O
known	O
as	O
[	B-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,5	I-IUPAC
-	I-IUPAC
dihydrophenylalanine	I-IUPAC
)	I-IUPAC
,	I-IUPAC
8	I-IUPAC
-	I-IUPAC
lysine	I-IUPAC
]	I-IUPAC
vasopressin	I-IUPAC
or	O
[	O
DiHPhe3	O
]	O
lysine	O
-	O
vasopressin	O
,	O
has	O
been	O
synthesized	O
in	O
an	O
attempt	O
to	O
utilize	O
2,5	B-IUPAC
-	I-IUPAC
dihydrophenylalanine	I-IUPAC
(	O
DiHPhe	O
)	O
to	O
evaluate	O
the	O
contribution	O
of	O
aromaticity	O
in	O
position	O
3	O
to	O
biological	O
activity	O
.	O
The	O
selectivity	O
index	O
(	O
SI	O
)	O
of	O
each	O
compound	O
was	O
obtained	O
by	O
dividing	O
its	O
50%	O
inhibitory	O
concentration	O
(	O
IC	O
(	O
50	O
)	O
)	O
against	O
Pc	O
,	O
Tg	O
,	O
or	O
Ma	O
DHFR	O
by	O
its	O
IC	O
(	O
50	O
)	O
against	O
rat	O
DHFR	O
.	O
Binding	O
potencies	O
of	O
these	O
compounds	O
to	O
receptor	O
sites	O
labeled	O
with	O
[	O
3H	O
]	O
dextromethorphan	O
(	O
[	O
3H	O
]	O
1	O
)	O
,	O
in	O
rat	O
brain	O
and	O
guinea	O
pig	O
brain	O
subcellular	O
fractions	O
,	O
and	O
[	O
3H	O
]	O
thienylcyclohexylpiperidine	O
(	O
TCP	O
)	O
and	O
[	O
3H	O
]	O
glycine	O
in	O
rat	O
brain	O
,	O
were	O
determined	O
.	O
In	O
order	O
to	O
study	O
the	O
structure	O
-	O
activity	O
relationships	O
of	O
L	B-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
2S	I-PARTIUPAC
,	I-PARTIUPAC
4S	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
L	B-IUPAC
-	I-IUPAC
(	I-IUPAC
2S	I-IUPAC
,	I-IUPAC
4R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
dioxolanyl	I-IUPAC
nucleoside	I-IUPAC
as	O
potential	O
anti	O
-	O
HIV	O
agents	O
,	O
various	O
enantiomerically	O
pure	O
L	B-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
2S	I-PARTIUPAC
,	I-PARTIUPAC
4S	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
(	B-IUPAC
2S	I-IUPAC
,	I-IUPAC
4R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
dioxolanylpyrimidine	I-IUPAC
and	O
-	B-PARTIUPAC
purine	I-PARTIUPAC
nucleosides	I-PARTIUPAC
have	O
been	O
synthesized	O
and	O
evaluated	O
against	O
HIV	O
-	O
1	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
(	O
PBM	O
)	O
cells	O
.	O
Med.	O
Chem.	O
1992	O
,	O
35	O
,	O
4334-4343	O
)	O
we	O
conformationally	O
restricted	O
the	O
sigma	O
-	O
receptor	O
ligand	O
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
pyrrolidinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dichlorophenyl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methylethylamine	I-IUPAC
(	O
1	O
)	O
by	O
incorporating	O
it	O
into	O
a	O
series	O
of	O
homologous	O
piperazines	O
3-9	O
and	O
homopiperazines	O
10	O
and	O
11	O
,	O
diazabicyclononanes	O
and	O
decanes	O
,	O
bridgehead	O
bicyclooctanes	O
and	O
nonanes	O
as	O
well	O
as	O
other	O
miscellaneous	O
compounds	O
.	O
Therefore	O
bis	B-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
acetamidophenyl	I-IUPAC
)	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
prolylpyrrolidine	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
R	I-IUPAC
,	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
phosphonate	I-IUPAC
(	O
11e	O
)	O
is	O
considered	O
as	O
a	O
major	O
improvement	O
and	O
will	O
be	O
a	O
highly	O
valuable	O
DPP	O
IV	O
inhibitor	O
for	O
further	O
studies	O
on	O
the	O
biological	O
function	O
of	O
the	O
enzyme	O
and	O
the	O
therapeutic	O
value	O
of	O
its	O
inhibition	O
.	O
Selectivity	O
for	O
the	O
NMDA	O
receptor	O
ion	O
channel	O
sites	O
over	O
sigma	O
receptors	O
appears	O
to	O
be	O
dependent	O
upon	O
the	O
structure	O
of	O
the	O
additional	O
substituents	O
on	O
the	O
guanidine	O
nitrogen	O
atoms	O
bearing	O
the	O
aryl	O
groups	O
.	O
Condensation	O
of	O
cyanothioacetamide	O
(	O
4	O
)	O
with	O
ethyl	B-IUPAC
alpha	I-IUPAC
-	I-IUPAC
(	I-IUPAC
ethoxymethylene	I-IUPAC
)	I-IUPAC
acetoacetate	I-IUPAC
(	O
5b	O
)	O
,	O
ethyl	B-IUPAC
4	I-IUPAC
-	I-IUPAC
ethoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
ethoxymethylene	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
oxobutanoate	I-IUPAC
(	O
5c	O
)	O
,	O
ethyl	B-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
ethoxymethylene	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phenylpropanoate	I-IUPAC
(	O
5d	O
)	O
afforded	O
exclusively	O
the	O
corresponding	O
6	O
-	O
substituted	O
pyridines	O
(	O
6b	O
-	O
d	O
)	O
.	O
However	O
,	O
the	O
bicyclic	O
hydantoins	O
were	O
much	O
less	O
potent	O
binders	O
to	O
the	O
neuronal	O
voltage	O
-	O
dependent	O
sodium	O
channel	O
than	O
their	O
monocyclic	O
counterparts	O
.	O
Treatment	O
of	O
the	O
5'	B-IUPAC
-	I-IUPAC
carboxaldehyde	I-IUPAC
derived	O
by	O
Moffatt	O
oxidation	O
of	O
6	B-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
benzoyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
isopropylideneadenosine	I-IUPAC
(	O
1	O
)	O
with	O
the	O
"	O
(	B-IUPAC
bromofluoromethylene	I-IUPAC
)	I-IUPAC
triphenylphosphorane	I-IUPAC
"	O
reagent	O
and	O
deprotection	O
gave	O
9	B-IUPAC
-	I-IUPAC
(	I-IUPAC
6	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
5	I-IUPAC
,	I-IUPAC
6	I-IUPAC
-	I-IUPAC
dideoxy	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
d	I-IUPAC
-	I-IUPAC
ribo	I-IUPAC
-	I-IUPAC
hex	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
enofuranosyl	I-IUPAC
)	I-IUPAC
adenine	I-IUPAC
(	O
4	O
)	O
.	O
Most	O
potent	O
among	O
the	O
bicyclic	O
derivatives	O
was	O
2	B-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
5,6	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
tetrazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
biphenyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
meth	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3H	I-IUPAC
-	I-IUPAC
imidazo	I-IUPAC
[	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,2,4	I-IUPAC
]	I-IUPAC
triazole	I-IUPAC
(	O
93	O
,	O
IC50	O
7.8	O
nM	O
)	O
.	O
The	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
B	O
-	O
ring	O
analogues	O
of	O
3	O
inhibit	O
DHFR	O
activity	O
and	O
tumor	O
cell	O
colony	O
formation	O
as	O
well	O
as	O
,	O
or	O
better	O
than	O
,	O
the	O
parent	O
compound	O
.	O
Five	O
new	O
analogues	O
(	O
1c	O
-	O
g	O
)	O
of	O
the	O
antifolate	O
N10	B-IUPAC
-	I-IUPAC
propargyl	I-IUPAC
-	I-IUPAC
5,8	I-IUPAC
-	I-IUPAC
dideazafolic	I-IUPAC
acid	I-IUPAC
(	O
1a	O
)	O
are	O
described	O
in	O
which	O
the	O
benzoyl	B-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamate	I-IUPAC
moiety	B-MODIFIER
was	O
replaced	O
by	O
benzoic	O
acid	O
(	O
desglutamyl	B-IUPAC
-	I-IUPAC
N10	I-IUPAC
-	I-IUPAC
propargyl	I-IUPAC
-	I-IUPAC
5,8	I-IUPAC
-	I-IUPAC
dideazafolic	I-IUPAC
acid	I-IUPAC
)	O
,	O
benzoyl	B-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
aspartate	I-IUPAC
,	O
4	B-IUPAC
-	I-IUPAC
phenylbutyrate	I-IUPAC
,	O
benzoylglycine	O
,	O
and	O
benzoyl	B-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
alanine	I-IUPAC
.	O
Glycosylation	O
of	O
4	B-IUPAC
(	I-IUPAC
5	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methylimidazole	I-IUPAC
-	I-IUPAC
5	I-IUPAC
(	I-IUPAC
4	I-IUPAC
)	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
with	O
3,5	B-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
toluoyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
erythro	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
chloride	I-IUPAC
via	O
mercuric	O
cyanide	O
method	O
provided	O
an	O
anomeric	O
mixture	O
of	O
the	O
blocked	O
5	B-IUPAC
-	I-IUPAC
methylimidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
deoxynucleoside	I-IUPAC
14	O
along	O
with	O
an	O
anomeric	O
mixture	O
of	O
the	O
4	B-IUPAC
-	I-IUPAC
methyl	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
isomer	B-MODIFIER
15	O
.	O
We	O
also	O
noted	O
that	O
further	O
deletions	O
(	O
residues	O
8-14	O
)	O
produced	O
antagonists	O
such	O
as	O
astressin	O
\C2	O
\BF	O
cyclo	O
(	O
30-33	O
)	O
[	O
DPhe12	O
,	O
Nle21	O
,	O
38	O
,	O
Glu30	O
,	O
Lys33	O
]	O
hCRF	O
(	O
12-41	O
)	O
\C2	O
\BF	O
(	O
1	O
)	O
.	O
;	O
Wins	O
,	O
P	O
.	O
In	O
the	O
indole	O
series	O
,	O
certain	O
alkylsulfonyl	O
amides	O
possessing	O
a	O
3	B-IUPAC
-	I-IUPAC
cyanobenzyl	I-IUPAC
substituent	B-MODIFIER
at	O
the	O
N	O
-	O
1	O
position	O
(	O
60	O
,	O
61	O
)	O
were	O
produced	O
that	O
had	O
KB	O
less	O
than	O
or	O
equal	O
to	O
10	O
(	O
-	O
9	O
)	O
M	O
on	O
guinea	O
pig	O
trachea	O
.	O
Debenzoylation	O
of	O
these	O
nucleosides	O
(	O
5a	O
-	O
c	O
)	O
gave	O
the	O
corresponding	O
3	B-PARTIUPAC
-	I-PARTIUPAC
bromo	I-PARTIUPAC
-	I-PARTIUPAC
,	O
3	B-PARTIUPAC
-	I-PARTIUPAC
cyano	I-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
3	B-IUPAC
-	I-IUPAC
(	I-IUPAC
methylthio	I-IUPAC
)	I-IUPAC
allopurinol	I-IUPAC
nucleosides	B-MODIFIER
(	O
6a	O
-	O
c	O
)	O
.	O
Compound	O
21	O
(	O
L	O
-	O
698,544	O
)	O
is	O
active	O
(	O
ED50	O
=	O
13.2	O
mg	O
/	O
kg	O
)	O
in	O
the	O
DBA	O
/	O
2	O
mouse	O
anticonvulsant	O
model	O
and	O
is	O
the	O
most	O
potent	O
combined	O
glycine	O
/	O
NMDA	O
-	O
AMPA	O
antagonist	O
yet	O
reported	O
,	O
in	O
vivo	O
,	O
and	O
may	O
prove	O
to	O
be	O
a	O
useful	O
pharmacological	O
tool	O
.	O
These	O
results	O
show	O
that	O
when	O
the	O
structure	O
of	O
the	O
target	O
protein	O
is	O
unknown	O
,	O
the	O
stereochemical	O
diversity	O
-	O
oriented	O
approach	O
can	O
be	O
a	O
powerful	O
strategy	O
in	O
medicinal	O
chemical	O
studies	O
.	O
The	O
biological	O
activity	O
of	O
these	O
heteroarotinoids	O
was	O
assayed	O
by	O
either	O
the	O
suppression	O
of	O
the	O
12	B-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
tetradecanoylphorbol	I-IUPAC
13	I-IUPAC
-	I-IUPAC
acetate	I-IUPAC
(	O
TPA	O
)	O
induced	O
synthesis	O
of	O
ornithine	O
decarboxylase	O
(	O
ODC	O
)	O
in	O
mouse	O
skin	O
or	O
the	O
induction	O
of	O
differentiation	O
of	O
human	O
(	O
HL	O
-	O
60	O
)	O
promyelocytic	O
cells	O
.	O
Whereas	O
most	O
analogues	O
derived	O
from	O
substituted	O
purine	O
and	O
pyrimidine	O
bases	O
and	O
bearing	O
various	O
hydroxy	B-MODIFIER
-	I-MODIFIER
or	O
amino	B-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
alkyl	B-IUPAC
chains	B-MODIFIER
did	O
not	O
show	O
evidence	O
of	O
antiviral	O
activity	O
at	O
a	O
concentration	O
of	O
2	O
mM	O
,	O
(	O
S	O
)	O
-	O
DHPA	O
inhibited	O
both	O
vaccinia	O
and	O
vesicular	O
stomatitis	O
virus	O
replication	O
at	O
0.05-0.1	O
mM	O
.	O
Interestingly	O
,	O
the	O
finding	O
that	O
polyamines	O
11	O
,	O
16	O
,	O
and	O
20	O
,	O
bearing	O
a	O
1,6	B-IUPAC
-	I-IUPAC
hexanediamine	I-IUPAC
moiety	B-MODIFIER
,	O
retained	O
high	O
affinity	O
for	O
alpha1	O
-	O
adrenoreceptor	O
subtypes	O
suggests	O
that	O
the	O
substituent	O
did	O
not	O
give	O
rise	O
to	O
negative	O
interactions	O
with	O
the	O
receptor	O
.	O
None	O
of	O
the	O
synthesized	O
nucleosides	O
was	O
toxic	O
up	O
to	O
100	O
microM	O
in	O
PBM	O
cells	O
.	O
Thus	O
,	O
the	O
binding	O
data	O
show	O
that	O
this	O
conformation	O
is	O
recognized	O
by	O
the	O
DAT	O
-	O
associated	O
binding	O
site	O
and	O
also	O
suggest	O
that	O
this	O
conformation	O
of	O
paroxetine	O
is	O
recognized	O
by	O
the	O
5	O
-	O
HTT	O
-	O
associated	O
binding	O
site	O
.	O
The	O
remaining	O
trans	O
-	O
4,5	O
-	O
di	O
-	O
Me	O
-	O
substituted	O
,	O
cis	O
-	O
and	O
trans	O
-	O
4,7	O
-	O
di	O
-	O
Me	O
-	O
substituted	O
,	O
and	O
all	O
4,5	O
-	O
,	O
5,6	O
-	O
,	O
6,7	O
-	O
,	O
and	O
7,8	O
-	O
fused	O
disubstituted	O
analogues	O
of	O
1	O
possessed	O
no	O
noticeable	O
desired	O
activity	O
.	O
Compound	O
37	O
,	O
3	B-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyrimidinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
piperazinyl	I-IUPAC
]	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
hexahydro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
,	I-IUPAC
7	I-IUPAC
-	I-IUPAC
etheno	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
cyclobut	I-IUPAC
[	I-IUPAC
f	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
benzisothiazol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
(	I-IUPAC
2H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
1,1	I-IUPAC
-	I-IUPAC
dioxide	I-IUPAC
,	O
buspirone	O
,	O
and	O
ipsapirone	O
showed	O
similarities	O
in	O
their	O
neurochemical	O
and	O
behavioral	O
profiles	O
.	O
In	O
murine	O
biodistribution	O
studies	O
,	O
[	O
131I	O
]	O
MIH	O
-	O
NGA	O
exhibited	O
rapid	O
accumulation	O
in	O
the	O
liver	O
followed	O
by	O
radioactivity	O
elimination	O
from	O
the	O
liver	O
at	O
a	O
rate	O
that	O
was	O
identical	O
to	O
and	O
faster	O
than	O
those	O
of	O
131I	O
-	O
labeled	O
NGA	O
via	O
direct	O
iodination	O
(	O
[	O
131I	O
]	O
NGA	O
)	O
and	O
[	O
131I	O
]	O
ATE	O
-	O
labeled	O
NGA	O
,	O
respectively	O
.	O
This	O
implies	O
interesting	O
differences	O
in	O
N	O
-	O
substituent	O
sensitivity	O
for	O
the	O
different	O
classes	O
of	O
compounds	O
with	O
respect	O
to	O
the	O
direction	O
of	O
their	O
respective	O
N	O
-	O
substituents	O
at	O
the	O
drug	O
-	O
receptor	O
interaction	O
.	O
v	O
.	O
We	O
have	O
previously	O
shown	O
that	O
the	O
2	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolyl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
AMPA	O
)	O
receptor	O
agonist	O
,	O
2	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolyl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
ACPA	O
,	O
2	O
)	O
,	O
binds	O
to	O
AMPA	O
receptors	O
in	O
a	O
manner	O
different	O
from	O
that	O
of	O
AMPA	O
(	O
1	O
)	O
itself	O
and	O
that	O
2	O
,	O
in	O
contrast	O
to	O
1	O
,	O
also	O
binds	O
to	O
kainic	O
acid	O
receptor	O
sites	O
.	O
The	O
remaining	O
compounds	O
generally	O
had	O
IC50	O
values	O
in	O
the	O
0.1-1.0	O
microM	O
range	O
.	O
They	O
displayed	O
only	O
low	O
to	O
moderate	O
affinity	O
for	O
these	O
sites	O
(	O
pA	O
(	O
2	O
)	O
&	O
lt	O
;	O
6	O
)	O
.	O
Inclusion	O
of	O
thymidine	O
did	O
not	O
establish	O
TS	O
as	O
the	O
site	O
of	O
cytotoxic	O
action	O
for	O
either	O
4	O
or	O
PDDF	O
in	O
the	O
cell	O
lines	O
used	O
.	O
A	O
few	O
indoles	O
belonging	O
to	O
the	O
previously	O
investigated	O
benzylamides	O
1	O
and	O
phenylhydrazides	O
2	O
were	O
synthesized	O
and	O
tested	O
to	O
enrich	O
the	O
SARs	O
in	O
these	O
two	O
series	O
.	O
Recently	O
,	O
we	O
reported	O
the	O
first	O
human	O
study	O
of	O
[	O
99mTc	O
]	O
TRODAT	O
-	O
1	O
,	O
technetium	O
,	O
2	B-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
[	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
[	I-PARTIUPAC
[	I-PARTIUPAC
3	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
chlorophenyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
8	I-PARTIUPAC
-	I-PARTIUPAC
methyl	I-PARTIUPAC
-	I-PARTIUPAC
8	I-PARTIUPAC
-	I-PARTIUPAC
azabicyclo	I-PARTIUPAC
[	O
3.2.1	O
]	O
oct	B-PARTIUPAC
-	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
yl	I-PARTIUPAC
]	I-PARTIUPAC
methyl	I-PARTIUPAC
]	I-PARTIUPAC
(	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
mercaptoethyl	I-PARTIUPAC
)	I-PARTIUPAC
amino	I-PARTIUPAC
]	I-PARTIUPAC
ethyl	I-PARTIUPAC
]	I-PARTIUPAC
amino	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
ethanethiolato	I-PARTIUPAC
(	I-PARTIUPAC
3	I-PARTIUPAC
-	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
o	I-PARTIUPAC
xo	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
1R	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
exo	I-PARTIUPAC
-	I-PARTIUPAC
exo	I-PARTIUPAC
)	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
,	O
as	O
an	O
imaging	O
agent	O
of	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
dopamine	O
transporters	O
.	O
Reaction	O
of	O
3	O
-	O
-	O
5	O
and	O
7	O
with	O
bis	B-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloroethyl	I-IUPAC
)	I-IUPAC
amine	I-IUPAC
led	O
to	O
the	O
corresponding	O
pyrazole	O
nitrogen	O
mustards	O
10	O
-	O
-	O
13	O
.	O
The	O
cancer	O
chemopreventive	O
activity	O
of	O
(	O
all	O
-	O
E	O
)	O
-	O
1	O
was	O
comparable	O
to	O
that	O
of	O
(	B-IUPAC
all	I-IUPAC
-	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
retinoic	I-IUPAC
acid	I-IUPAC
,	O
and	O
the	O
toxicity	O
was	O
comparable	O
to	O
or	O
slightly	O
better	O
than	O
that	O
of	O
the	O
natural	O
vitamin	O
.	O
The	O
potency	O
in	O
blocking	O
A1	O
-	O
adenosine	O
receptors	O
(	O
inhibition	O
of	O
binding	O
of	O
N6	B-IUPAC
-	I-IUPAC
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
cyclohexyladenosine	I-IUPAC
to	O
brain	O
membranes	O
)	O
and	O
A2	O
-	O
adenosine	O
receptors	O
(	O
inhibition	O
of	O
2	B-IUPAC
-	I-IUPAC
chloroadenosine	I-IUPAC
-	O
elicited	O
accumulations	O
of	O
cyclic	O
AMP	O
in	O
brain	O
slices	O
)	O
was	O
markedly	O
affected	O
by	O
structural	O
changes	O
distal	O
to	O
the	O
primary	O
pharmacophore	O
(	O
8	B-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dialkylxanthine	I-IUPAC
)	O
.	O
Condensation	O
of	O
3	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyrazinecarbonitrile	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxide	I-IUPAC
(	O
V	O
)	O
with	O
the	O
appropriately	O
substituted	O
amine	O
afforded	O
a	O
series	O
of	O
3	B-PARTIUPAC
-	I-PARTIUPAC
amino	I-PARTIUPAC
-	I-PARTIUPAC
6	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
[	I-PARTIUPAC
(	I-PARTIUPAC
aryl	I-PARTIUPAC
and	O
aralkyl	B-PARTIUPAC
)	I-PARTIUPAC
amino	I-PARTIUPAC
]	I-PARTIUPAC
methyl	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
pyrazinecarbonitrile	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
oxides	I-PARTIUPAC
VI	O
.	O
Most	O
of	O
the	O
compounds	O
showed	O
antihistaminic	O
activity	O
and	O
some	O
of	O
the	O
1	B-MODIFIER
-	I-MODIFIER
[	I-MODIFIER
2	I-MODIFIER
-	I-MODIFIER
(	I-MODIFIER
substituted	I-MODIFIER
-	I-MODIFIER
oxy	I-MODIFIER
)	I-MODIFIER
ethyl	I-MODIFIER
]	I-MODIFIER
derivatives	B-MODIFIER
exhibited	O
potent	O
activity	O
.	O
The	O
stereochemical	O
and	O
steric	O
demands	O
for	O
sigma	O
receptor	O
affinity	O
are	O
much	O
less	O
stringent	O
.	O
One	O
of	O
the	O
nonquaternary	O
compounds	O
,	O
3	B-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
oxadiazole	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
thiohydroximic	I-IUPAC
acid	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
diethylamino	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
S	I-IUPAC
-	I-IUPAC
ester	I-IUPAC
,	O
is	O
a	O
powerful	O
reversible	O
inhibitor	O
of	O
AChE	O
(	O
I50	O
=	O
7.5	O
microM	O
)	O
.	O
With	O
the	O
exception	O
of	O
the	O
3,4,5	B-IUPAC
-	I-IUPAC
triphenylpyrazole	I-IUPAC
derivative	B-MODIFIER
13g	O
,	O
compounds	O
presenting	O
the	O
(	B-IUPAC
m	I-IUPAC
-	I-IUPAC
ethylphenoxy	I-IUPAC
)	I-IUPAC
acetic	I-IUPAC
acid	I-IUPAC
side	B-MODIFIER
chain	I-MODIFIER
discovered	O
with	O
3	O
demonstrated	O
enhanced	O
potency	O
compared	O
to	O
the	O
analogously	O
substituted	O
alkanoic	O
acid	O
derivative	O
.	O
We	O
find	O
that	O
for	O
the	O
fluorine	O
-	O
substituted	O
derivatives	O
studied	O
,	O
the	O
position	O
of	O
the	O
fluorine	O
on	O
the	O
quinolone	O
nucleus	O
or	O
the	O
number	O
of	O
fluorine	O
atoms	O
does	O
not	O
seem	O
to	O
be	O
important	O
for	O
good	O
Gram	O
positive	O
activity	O
.	O
r	O
.	O
Inhibition	O
of	O
the	O
binding	O
of	O
[	B-IUPAC
3H	I-IUPAC
]	I-IUPAC
phorbol	I-IUPAC
-	I-IUPAC
12,13	I-IUPAC
-	I-IUPAC
dibutyrate	I-IUPAC
to	O
PK	O
-	O
C	O
alpha	O
showed	O
that	O
only	O
the	O
threo	O
-	O
isomer	O
,	O
5	B-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
tetradecanoyl	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dideoxy	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
threo	I-IUPAC
-	I-IUPAC
hexono	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
lactone	I-IUPAC
(	O
2	O
)	O
was	O
a	O
good	O
PK	O
-	O
C	O
ligand	O
(	O
Ki	O
=	O
1	O
microM	O
)	O
.	O
Relative	O
to	O
ethyl	B-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
deaza	I-IUPAC
-	I-IUPAC
7,8	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methylanilino	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
pteridine	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carbamate	I-IUPAC
(	O
11	O
)	O
and	O
the	O
corresponding	O
6	B-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
compound	B-MODIFIER
(	O
12	O
)	O
,	O
no	O
antitumor	O
activity	O
was	O
observed	O
with	O
7,8	B-IUPAC
-	I-IUPAC
dihydropteridines	I-IUPAC
,	O
3	B-IUPAC
-	I-IUPAC
deaza	I-IUPAC
-	I-IUPAC
7,8	I-IUPAC
-	I-IUPAC
dihydropteridines	I-IUPAC
,	O
and	O
the	O
corresponding	O
heteroaromatic	O
compounds	O
.	O
Under	O
the	O
same	O
conditions	O
,	O
nitroxyl	B-IUPAC
generation	O
from	O
6	O
was	O
minimal	O
,	O
a	O
result	O
compatible	O
with	O
a	O
previous	O
observation	O
that	O
nitroxyl	O
generation	O
from	O
N	B-IUPAC
-	I-IUPAC
hydroxysaccharin	I-IUPAC
(	O
7	O
)	O
,	O
the	O
product	O
of	O
the	O
hydrolysis	O
of	O
the	O
carbethoxy	B-IUPAC
group	B-MODIFIER
of	O
6	O
,	O
was	O
minimal	O
at	O
physiological	O
pH	O
.	O
In	O
general	O
,	O
the	O
chloro	O
and	O
bromo	O
analogs	O
were	O
more	O
effective	O
than	O
the	O
unsubstituted	O
naphthylalanines	O
as	O
growth	O
inhibitors	O
of	O
the	O
three	O
microorganisms	O
studied	O
.	O
This	O
report	O
focuses	O
on	O
the	O
synthesis	O
and	O
structure	O
-	O
activity	O
relationships	O
of	O
these	O
compounds	O
.	O
This	O
route	O
to	O
9b	O
intersects	O
reported	O
synthetic	O
approaches	O
leading	O
to	O
10	B-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
deazaaminopterin	I-IUPAC
(	O
10	O
-	O
EDAM	O
,	O
edatrexate	O
)	O
,	O
an	O
agent	O
now	O
in	O
advanced	O
clinical	O
trials	O
.	O
In	O
series	O
I	O
,	O
the	O
presence	O
of	O
a	O
phenol	B-PARTIUPAC
group	B-MODIFIER
,	O
irrespective	O
of	O
the	O
nature	O
of	O
tertioalkyl	B-PARTIUPAC
group	B-MODIFIER
,	O
imparted	O
at	O
least	O
partial	O
RAR	O
gamma	O
selectivity	O
,	O
whereas	O
in	O
series	O
II	O
,	O
the	O
presence	O
of	O
both	O
adamantyl	B-PARTIUPAC
and	O
phenol	B-PARTIUPAC
groups	B-MODIFIER
is	O
needed	O
to	O
confer	O
RAR	O
gamma	O
selectivity	O
.	O
Hydrogenation	O
of	O
8a	O
and	O
8b	O
at	O
their	O
9,10	O
-	O
double	O
bond	O
afforded	O
4	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
5,10	I-IUPAC
-	I-IUPAC
dideazapteroic	I-IUPAC
acid	I-IUPAC
methyl	I-IUPAC
ester	I-IUPAC
(	O
9a	O
)	O
and	O
4	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
deazapteroic	I-IUPAC
acid	I-IUPAC
methyl	I-IUPAC
ester	I-IUPAC
(	O
9b	O
)	O
.	O
Replacement	O
of	O
a	O
hydroxyl	B-IUPAC
group	B-MODIFIER
for	O
a	O
fluorine	O
atom	O
in	O
the	O
4	O
position	O
of	O
muscarine	O
produces	O
1	O
order	O
of	O
magnitude	O
increase	O
in	O
affinity	O
for	O
cardiac	O
M2	O
muscarinic	O
receptors	O
controlling	O
rate	O
,	O
while	O
the	O
affinity	O
at	O
cardiac	O
M2	O
muscarinic	O
receptors	O
controlling	O
force	O
is	O
unchanged	O
,	O
opening	O
the	O
possibility	O
of	O
a	O
further	O
classification	O
of	O
cardiac	O
muscarinic	O
receptors	O
.	O
Variation	O
of	O
the	O
bridge	O
linking	O
the	O
heterocyclic	O
ring	O
and	O
p	B-IUPAC
-	I-IUPAC
aminobenzoyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamate	I-IUPAC
portions	B-MODIFIER
of	O
our	O
previously	O
described	O
classical	O
2,4	B-IUPAC
-	I-IUPAC
diaminofuro	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
1	O
and	O
2	O
are	O
reported	O
as	O
inhibitors	O
of	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
and	O
thymidylate	O
synthase	O
(	O
TS	O
)	O
and	O
as	O
antitumor	O
agents	O
.	O
[	O
D	O
-	O
Trp	O
(	O
Boc	O
)	O
4	O
,	O
Lys	O
(	O
Boc	O
)	O
5	O
,	O
Thr	O
(	O
tBu	O
)	O
6	O
]	O
octreotide	O
was	O
utilized	O
for	O
the	O
solution	O
-	O
phase	O
synthesis	O
of	O
CPTA	O
-	O
D	O
-	O
Phe1	O
-	O
octreotide	O
,	O
where	O
CPTA	O
is	O
4	B-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
1,4,8,11	I-IUPAC
-	I-IUPAC
tetraazacyclotetradec	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
benzoic	I-IUPAC
acid	I-IUPAC
.	O
Among	O
all	O
the	O
synthesized	O
compounds	O
,	O
only	O
12	O
compounds	O
,	O
namely	O
3a	O
,	O
3c	O
,	O
3d	O
,	O
3f	O
,	O
4c	O
,	O
4d	O
,	O
4f	O
,	O
5a	O
,	O
6f	O
,	O
6h	O
,	O
6i	O
,	O
and	O
7h	O
,	O
have	O
exhibited	O
either	O
&	O
gt	O
;	O
90%	O
micro	O
-	O
or	O
macrofilaricidal	O
activity	O
or	O
sterlization	O
of	O
female	O
worms	O
.	O
1	B-IUPAC
-	I-IUPAC
[	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
Chloro	I-IUPAC
(	I-IUPAC
1,1	I-IUPAC
'	I-IUPAC
-	I-IUPAC
biphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
-	I-IUPAC
a1	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
piperdinyl	I-IUPAC
)	I-IUPAC
ethanone	I-IUPAC
hydrochloride	I-IUPAC
(	O
18	O
,	O
RMI	O
12436A	O
)	O
was	O
found	O
to	O
lower	O
serum	O
cholesterol	O
levles	O
in	O
rats	O
with	O
concurrent	O
accumulation	O
of	O
(	B-IUPAC
3beta	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cholesta	I-IUPAC
-	I-IUPAC
5,7	I-IUPAC
-	I-IUPAC
dien	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ol	I-IUPAC
,	O
suggesting	O
inhibition	O
of	O
7	B-IUPAC
-	I-IUPAC
dehydrocholesterol	I-IUPAC
delta7	O
-	O
reductase	O
.	O
[	O
DiHPhe3	O
]	O
lysine	O
-	O
vasopressin	O
exhibited	O
125	O
-	O
-	O
130	O
units	O
/	O
mg	O
of	O
antidiuretic	O
,	O
129	O
-	O
-	O
132	O
units	O
/	O
mg	O
of	O
rat	O
pressor	O
,	O
and	O
6	O
units	O
/	O
mg	O
of	O
rat	O
uterus	O
contracting	O
activity	O
.	O
In	O
some	O
cases	O
,	O
C	O
-	O
alkylation	O
also	O
occurred	O
.	O
Thus	O
,	O
(	B-IUPAC
1S	I-IUPAC
,	I-IUPAC
3R	I-IUPAC
,	I-IUPAC
6S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Z	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
biphenylylmethylene	I-IUPAC
)	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
azatricyclo	I-IUPAC
[	I-IUPAC
4.3.1	I-IUPAC
.	I-IUPAC
Conformational	O
analysis	O
of	O
the	O
stereoisomers	O
,	O
assuming	O
rotation	O
of	O
the	O
aryl	O
substituent	O
and	O
ester	O
groups	O
,	O
shows	O
small	O
energy	O
differences	O
(	O
about	O
4	O
kcal	O
.	O
Deprotection	O
afforded	O
6	O
,	O
which	O
was	O
condensed	O
with	O
expoxides	O
or	O
alkyl	O
halides	O
to	O
furnish	O
the	O
title	O
compounds	O
.	O
These	O
results	O
are	O
in	O
agreement	O
with	O
other	O
studies	O
suggesting	O
the	O
presence	O
of	O
a	O
lipophilic	O
pocket	O
in	O
the	O
AR	O
binding	O
site	O
that	O
is	O
filled	O
by	O
moderately	O
sized	O
cycloalkyl	O
rings	O
at	O
the	O
N	O
(	O
6	O
)	O
position	O
of	O
both	O
adenine	O
and	O
adenosine	O
derivatives	O
.	O
The	O
free	O
ligands	O
,	O
their	O
Zn	O
(	O
II	O
)	O
complexes	O
,	O
and	O
the	O
ferric	O
complex	O
of	O
3,4,3	O
-	O
LIHOPO	O
were	O
administered	O
to	O
mice	O
[	O
30	O
mumol	O
/	O
kg	O
intraperitoneally	O
1	O
h	O
after	O
Pu	O
(	O
IV	O
)	O
-	O
238	O
citrate	O
,	O
kill	O
at	O
24	O
h	O
]	O
.	O
Finally	O
,	O
two	O
tripeptides	O
containing	O
O'	B-IUPAC
-	I-IUPAC
(	I-IUPAC
epoxyalkyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
tryosines	I-IUPAC
were	O
synthesized	O
[	O
N	B-IUPAC
-	I-IUPAC
(	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butoxycarbonyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
alanyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
alanyl	I-IUPAC
-	I-IUPAC
O'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
epoxypropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
tyrosi	I-IUPAC
ne	I-IUPAC
ethyl	I-IUPAC
ester	I-IUPAC
and	O
N	B-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoroacetyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
valyl	I-IUPAC
-	I-IUPAC
O'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
epoxypropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
tyrosyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
valine	I-IUPAC
methyl	I-IUPAC
ester	I-IUPAC
]	O
as	O
potential	O
elastase	O
inhibitors	O
and	O
were	O
found	O
to	O
reversibly	O
and	O
competitively	O
inhibit	O
porcine	O
pancreatic	O
elastase	O
.	O
avium	O
DHFR	O
was	O
the	O
2'	B-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butynyl	I-IUPAC
)	I-IUPAC
dibenz	I-IUPAC
[	I-IUPAC
b	I-IUPAC
,	I-IUPAC
f	I-IUPAC
]	I-IUPAC
azepinyl	I-IUPAC
derivative	B-MODIFIER
20	O
(	O
IC	O
(	O
50	O
)	O
=	O
2.9	O
nM	O
)	O
,	O
whereas	O
the	O
most	O
selective	O
was	O
the	O
2'	B-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
pentynyl	I-IUPAC
)	I-IUPAC
analogue	B-MODIFIER
21	O
,	O
with	O
SI	O
values	O
of	O
&	O
gt	O
;	O
100	O
against	O
both	O
P	O
.	O
Isoquinoline	O
and	O
some	O
pyridopyrimidine	O
derivatives	O
were	O
completely	O
inactive	O
;	O
therefore	O
,	O
1	B-IUPAC
-	I-IUPAC
aza	I-IUPAC
has	O
an	O
important	O
role	O
.	O
CV	O
-	O
11974	O
at	O
0.1-1	O
mg	O
/	O
kg	O
iv	O
reduced	O
blood	O
pressure	O
dose	O
-	O
dependently	O
in	O
spontaneously	O
hypertensive	O
rats	O
.	O
falciparum	O
with	O
two	O
exhibiting	O
values	O
of	O
14	O
nM	O
.	O
Thf2	O
-	O
FU	O
was	O
easily	O
hydrolyzed	O
to	O
Thf	O
-	O
FU	O
.	O
Binding	O
in	O
sst	O
(	O
4	O
)	O
-	O
transfected	O
cells	O
was	O
completely	O
displaced	O
by	O
SRIF	O
-	O
28	O
or	O
the	O
sst	O
(	O
4	O
)	O
-	O
selective	O
L	O
-	O
803,087	O
.	O
According	O
to	O
their	O
selectivity	O
for	O
the	O
B	O
-	O
cell	O
(	O
endocrine	O
tissue	O
)	O
vs	O
the	O
vascular	O
(	O
smooth	O
muscle	O
tissue	O
)	O
ionic	O
channel	O
,	O
selected	O
3	B-IUPAC
-	I-IUPAC
(	I-IUPAC
alkylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4H	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
4,3	I-IUPAC
-	I-IUPAC
e	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
,	I-IUPAC
-	I-IUPAC
thiadiazine	I-IUPAC
1,1	I-IUPAC
-	I-IUPAC
dioxides	I-IUPAC
may	O
serve	O
as	O
pharmacological	O
tools	O
in	O
studying	O
the	O
K	O
(	O
ATP	O
)	O
channels	O
(	O
"	O
pancreatic	O
-	O
like	O
"	O
K	O
(	O
ATP	O
)	O
channels	O
)	O
in	O
other	O
tissues	O
.	O
Whereas	O
(	B-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
4,5,6,7	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
benzisoxazole	I-IUPAC
(	O
8	O
,	O
exo	O
-	O
THPO	O
)	O
was	O
synthesized	O
via	O
aluminum	O
amalgam	O
reduction	O
of	O
oxime	O
22a	O
or	O
22b	O
,	O
compounds	O
9	O
,	O
11-13	O
,	O
and	O
15-17	O
were	O
obtained	O
via	O
reductive	O
aminations	O
.	O
The	O
ligands	O
disclosed	O
herein	O
provide	O
additional	O
pharmacological	O
tools	O
of	O
use	O
in	O
attempting	O
to	O
correlate	O
structure	O
and	O
transporter	O
selectivity	O
with	O
in	O
vivo	O
studies	O
of	O
behavioral	O
outcomes	O
.	O
[	O
1	O
-	O
Beta	O
-	O
mercapto	O
-	O
beta	O
,	O
beta	O
-	O
pentamethylenepropionic	O
acid	O
]	O
oxytocin	O
was	O
prepared	O
from	O
beta	O
-	O
Mpa	O
(	O
beta	O
-	O
(	O
CH2	O
)	O
5	O
)	O
(	O
Bzl	O
)	O
-	O
Tyr	O
(	O
Bzl	O
)	O
-	O
Ile	O
-	O
Gln	O
-	O
Asn	O
-	O
Cys	O
(	O
Bzl	O
)	O
-	O
Pro	O
-	O
Leu	O
-	O
Gly	O
-	O
NH2	O
by	O
removal	O
of	O
the	O
Bzl	O
-	O
protecting	O
groups	O
with	O
Na	O
-	O
NH3	O
followed	O
by	O
cyclization	O
of	O
the	O
resulting	O
disulfhydryl	O
compound	O
with	O
K3Fe	O
(	O
CN	O
)	O
6	O
.	O
Orally	O
administered	O
3,4,3	O
-	O
LI	O
-	O
(	O
diCAM	O
-	O
diHOPO	O
)	O
promoted	O
significantly	O
more	O
Pu	O
excretion	O
than	O
an	O
equimolar	O
amount	O
of	O
CaNa3DTPA	O
.	O
The	O
resulting	O
2	B-MODIFIER
-	I-MODIFIER
unsubstituted	I-MODIFIER
3H	B-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
triazol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
were	O
then	O
alkylated	O
,	O
yielding	O
2,4	B-IUPAC
-	I-IUPAC
dialkyl	I-IUPAC
-	I-IUPAC
3H	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
triazol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
.	O
